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The gastrointestinal tract contains multiple types of immune cells that induce various 
immune responses to dietary antigens, commensal bacteria, and pathogens. Maintaining 
homeostasis at this mucosal barrier requires stringent regulation of the immune responses, 
including mechanisms to convey information about environmental conditions. Dietary 
nutrients can be converted into gut metabolites through either host or microbial 
enzymatic activities. Accumulating evidence demonstrates that these gut metabolites 
have a significant impact on the regulation of intestinal immune responses; however, the 
underlying mechanisms by which gut metabolites regulate the intestinal immune system 
are incompletely understood. Thus, we have studied the role of gut metabolites, 
specifically short chain fatty acids (SCFAs) and retinoic acid (RA), in regulation of 
intestinal immune responses. Our research revealed novel pathways that SCFAs and RA 
use to contribute to anti-bacteria immunity through modulation of epithelial cells and 
innate lymphoid cells (ILCs), respectively.  
 SCFAs are the major metabolites of dietary fibers and produced from microbial 
fermentation in the colon.  A mounting body of evidence indicates that SCFAs regulate 




We investigated regulation of the intestinal inflammatory responses by SCFAs and 
their receptors, GPR41 and GPR43. The control and SCFA-fed wild type (WT), GPR41-/-, 
and GPR43-/- mice were chemically challenged with ethanol and 2, 4, 6-trinitrobenzene 
sulfonic-acid (TNBS) or infected with Citrobacter rodentium to gain insights on the roles 
of SCFA signaling in inflammatory responses. From these in vivo studies, we reported 
that GPR41-/- and GPR43-/- mice had abnormally hypo-inflammatory responses following 
chemical challenges. They also had a delayed immune response in clearing C. rodentium 
compared to WT mice. SCFA treatment caused intestinal epithelial cells (ECs) to 
produce inflammatory mediators both in vitro and in vivo in a GPR41- and GPR43-
dependent manner. These processes were necessary to recruit neutrophils and induce 
effector T cells differentiation in the intestine after immune challenges. The underlying 
mechanism is that SCFA receptors activated extracellular signal-regulated kinases 
(ERK1/2) and p38 mitogen-activated protein kinase (MAPK) signaling pathways in ECs 
for production of inflammatory cytokines and chemokines.  
Separately, we studied the role of the gut metabolite, RA, in regulating innate 
immunity in the intestine. RA is a vitamin A metabolite known to regulate various 
immune responses, including development, function, and migration of lymphocytes in the 
intestine. However, the roles of RA in innate lymphocyte biology are insufficiently 
defined. We identified a novel function of RA in the migration program of ILCs, a class 
of newly identified innate lymphocytes to the gut. This regulatory function of RA has a 
significant impact on anti-bacterial immunity in the gut. We reported that intestinal ILCs 
must undergo a ‘homing receptor (HR) switch’ from a secondary lymphoid tissue 




Mucosal dendritic cells (DCs)-derived RA induced this HR switch, which is required for 
effector function of ILCs in the intestine. However, the RA-mediated HR switch occurred 
only in ILC1 and ILC3 subsets, but not ILC2s.  In contrast, ILC2s acquired gut HRs 
during their development in the bone marrow and BM ILC2 precursors could migrate 
directly to the intestine. Vitamin A deficient (VAD) mice exhibited higher susceptibility 
to C. rodentium infection with decreased ILC3 numbers in the gut compared to mice fed 
vitamin A normal diet (VAN). We demonstrated that efficient anti-pathogenic bacterial 




CHAPTER 1. LITERATURE REVIEW 
1.1 Role of short chain fatty acids on the regulation of intestinal immunity 
The gastrointestinal tract is exposed to multifarious dietary and commensal 
bacterial antigens. The maintenance of immune tolerance to harmless antigens is 
necessary for gut health; yet, the capacity to mount efficient immune responses to 
pathogens is also crucial. The mechanisms that regulate intestinal immune responses 
remain incompletely understood. Commensal bacteria benefit the host through production 
of various microbial factors. For example, commensal bacteria metabolize soluble dietary 
fibers and produce short chain fatty acids (SCFAs) in the colon. It has been generally 
accepted that SCFAs have beneficial impacts on maintenance of gut health. In this 
introduction, we will review the production and absorption of SCFAs, as well as 
expression of their transporters and receptors by cells, and function of SCFAs in the 
regulation of intestinal immune responses. 
 
1.1.1 Production of short chain fatty acids 
Host and gut microbial flora are functionally integrated through co-evolution for 
mutual benefits. In the gastrointestinal tract commensal bacteria are most densely 
populated in the colon, where they exert their effects on the host, largely through 




hain fatty acids, which are mainly produced from dietary fibers and non-digestible 
carbohydrates through bacterial fermentation. The major species of SCFAs are acetate 
(C2), propionate (C3), and butyrate (C4), with relative proportions of C2, C3, C4 in the 
colonic lumen being 6:3:1 (1, 2). In the colon tissue, most SCFAs are absorbed into 
colonocytes and provide energy for colonocyte biology (3). SCFAs are absorbed into 
epithelial cells through SCFA-HCO3 exchange and further transported to distant tissues 
including the liver, skeletal muscles, and the pancreas (4-6).  
 
1.1.2 Receptors and transporters of short chain fatty acids 
SCFAs can be absorbed into cells through diffusion or transported into cells 
through monocarboxylate/solute transporters which expressed by intestinal epithelial 
cells (7). The Na+-coupled transporters, SLC16A1 and SLC5A8, mediate SCFA transport 
into epithelial cells (8, 9). These transporters are known to be involved in functional roles 
of SCFAs such as HDAC inhibition (10, 11). SCFAs can also regulate functional 
activities of cell without actually entering it. This is mediated by activating SCFA-
specific receptors, namely surface G-protein-coupled receptors such as GPR41, GPR43, 
and GPR109A (Fig. 1.1). SCFAs, especially C3 and C4, can activate GPR41 (also called 
free fatty acid receptor 3, FFA3) (12). GPR41 is expressed by many cell types including 
intimal epithelial cells, pancreas, spleen, and adipose tissues (12, 13). The expression of 
GPR43 (FFA2) was reported that certain immune cells (phagocytes), adipocytes and 
epithelial cells (14-16). GPR109A (also called hydroxycarboxylic acid receptor 2, HCA2) 
is known to be activated by C4 and niacin as well (17-19). GPR109A is expressed in 




Upon binding of SCFAs to G-protein receptors, the cytoplasmic region of the 
receptors are coupled to G-protein family Gαi/o or  Gαq, which regulate the adenylate 
cyclase pathway and the phospholipase C (PLC) pathway, respectively (21, 22). Binding 
of GPCR by ligands induces activation of mitogen-activated protein kinases (MAPKs) 
(p38 and ERK), protein kinase C (PKC), which leads to activates key cellular processes 
such as proliferation, motility, and regulation of gene expression (e.g. expression of 
cytokines and chemokines) (23). 
 
1.1.3 Function of short chain fatty acid in the regulation of intestinal inflammation 
 It has been generally accepted that dietary fiber intake contributes the 
maintenance of gut health. Numerous sources indicate that dietary fiber or SCFA 
administration regulates intestinal inflammation in both humans and mice.  These 
beneficial effects of SCFAs are mainly mediated by regulation of certain immune cell 
types, such as intestinal epithelial cells, T cells, and phagocytes. In this section, we will 
discuss functional roles of SCFAs on the regulation of intestinal immune responses 
through specific immune cells types. We will review impacts of SCFAs on epithelial cells, 
T-cells, and phagocytes.   
Intestinal epithelial cells are not simply a physical barrier in the intestine. Intestinal 
epithelial cells can be considered immune cells, given that they play significant roles in 
regulation of intestinal immune responses through recognition of antigens and production 
of various immune modulators. SCFAs can be internalized by intestinal epithelial cells or 
activate the SCFA receptors on intestinal epithelial cells. Therefore, the biological 




intestine. Among SCFAs, C4 (and to a lesser extent C2 and C3) can be readily utilized by 
colonocytes as an energy source (3). C4 regulates survival, apoptosis, proliferation, and 
differentiation of colonocytes through the control of the cell cycle (24, 25). The 
underlying mechanism is C4-mediated hyperacetylation of histones, resulting in 
enhanced accessibility of the transcriptional machinery for gene expression, which 
regulate cellular responses (26, 27). For example, C4-mediated HDAC inhibition is 
known to regulate the cell cycle inhibitor, p21Waf1/Cip1, and the pro-apoptotic protein, 
BAK, in transformed cells (28, 29).The most important role of intestinal epithelial cells is 
providing a barrier between luminal antigens and intestinal tissues. The separation 
between luminal contents and tissues can be mediated by physical and molecular means. 
The energy that SCFAs provide to epithelial cells contributes to maintenance of an intact 
epithelium, required for the physical barrier. Anti-microbial peptides and mucins protect 
the gastrointestinal mucosa against the invasion of pathogenic bacteria and gut 
microbiota (30-32). SCFAs regulate various antimicrobial peptides and mucins 
production by epithelial cells. C4 treatment enhances MUC2 expression and cathelicidin 
(LL-37) in epithelial cell lines (33, 34).  
Intestinal epithelial cells produce cytokines and chemokines upon recognition of 
danger signals such as commensal bacteria, pathogens, and allergens. A mounting body 
of evidence reports that SCFAs regulate production of various regulatory molecules by 
epithelial cells. SCFAs are known to suppress expression of inflammatory mediators, 
including IL-8, MCP-1, CXCL-1, and CXCL-10, from epithelial cells (35-37). Some 
reports indicate that SCFA receptors are involved in the production of cytokines by 




defective in producing IL-18 in response to C4 (38). GPR43 regulates inflammasome 
activation for IL-18 production in epithelial cells (39). 
T cells are one of the key players in the regulation of intestinal inflammation. There 
are some indications that SCFAs directly and indirectly regulate T-cell responses, 
including their differentiation and cytokine production in the gut. C4 inhibits lymphocyte 
proliferation with reduced IL-2 production (40, 41). SCFAs enhance IFN-γ and IL-10 
production by cultured lymphocytes in certain condition (42). Recently, it has been 
reported that SCFAs induce Treg generation, resulting in improved suppression of 
intestinal inflammation (43). The underlying mechanism is that GPR43-dependent 
HDAC inhibition by SCFAs induces FoxP3 expression in colonic T cells (44, 45). 
Another mechanism of SCFA-mediated T cell regulation is through control of mTOR 
activity (46). It has been reported that SCFAs increase mTOR activity (phosphorylation 
of S6K protein), which contributes to Th1 and Th17 cell differentiation and IL-10 
expression. The same study also reported that SCFAs induce hyper-acetylation of S6K in 
T cells, leading to increased mTOR activity (46). Collectively, SCFAs regulate T-cell 
differentiation and function through genomic hyperacetylation and metabolic changes 
(Fig. 1.1). 
Another potential target of SCFAs is phagocytes, including neutrophils, 
macrophages, and dendritic cells. A mounting body of evidence reported that SCFAs 
modulate activities of phagocytes in a SCFA-receptor-dependent or -independent manner. 
SCFAs regulate migration of neutrophils migration into inflamed tissue sites in a GPR43-
dependent manner (15, 22). It has been reported that MAPKs and PKC signaling 




neutrophils by SCFAs, through GPR43, contributes to the regulation of intestinal 
inflammation and immune responses. Also, SCFAs regulate the production of TNF-α, 
CINC-2αβ, and NO by neutrophils (47, 48). SCFAs can also affect production of 
inflammatory mediators by macrophages. Generally, SCFAs promote production of anti-
inflammatory mediators but suppress pro-inflammatory mediators from macrophages. 
For instance, C4 elevated IL-10 production but suppressed the production of TNF-α, IL-
1β, IL-6, and nitric oxide by macrophages (49). GPR109A is known to regulate IL-18 
production by colonic macrophages (38). SCFAs also affect dendritic cells, with the most 
well-reported function being control of development and maturation (50-52). Generally, 
SCFAs inhibit development and maturation of DCs. SCFAs suppressed DC development 
and maturation from BM progenitors in vitro (11). GPR109A activation regulates the 
phenotype of colonic macrophages and DCs, which in turn affects the generation of Treg 
cells (38).  
 
1.2 Role of retinoic acid on the regulation of immune responses and innate 
lymphoid cell migration 
 
1.2.1 Function of retinoic acid in the regulation of immune system 
Vitamin A deficiency is widely believed to lead to immune deficiencies in the 
body. Retinoic acid, a major vitamin A metabolite, regulates broad aspects of immune 
responses (53). Dietary vitamin A is absorbed in the gut tissue and transported into the 
blood circulation to enter the liver (54, 55). Upon entering liver cells, retinol or retinal 




57). RA can bind retinoic acid receptors (RAR) and retinoid X receptor (RXR) in the 
cytoplasm (57, 58). All-trans RA binds to RXR via heterodimers with RAR to regulate 
variety of gene expression. RA production is not limited to the liver; in gut-associated 
secondary lymphoid tissue, mucosal DCs process vitamin A and produce RA, effectively 
regulating local immune cell activity (59). RA has significant impacts on the 
differentiation, activation, and migration of lymphocytes (Fig. 1.2). RA promotes plasma 
cell differentiation and IgA expression in mucosal tissues (60-62). This is implicated in 
anti-bacterial immunity in the intestine. RA also regulates T-cell differentiation and 
activation. It has been reported that RA induces Treg generation in the intestine, which is 
implicated in the immune tolerance in the intestine (63, 64). RA also regulates effector T 
cell differentiation. Low dose of RA enhances Th17 cell differentiation (65). RA 
suppresses Th1 cell differentiation in vitro (66, 67). RA is also required for T-cell 
activation upon antigen priming. RARα deficiency induced an impaired Th1 response to 
T. gondii infection (68). RA as a gut tissue factor regulates gut tissue tropism of adaptive 
lymphocytes by upregulation of gut homing receptors (HR). Mucosal DC-derived RA 
induces the upregulation of gut homing receptors, CCR9 and α4β7, in T and B 
lymphocytes (69, 70). Vitamin A deficiency reduced gut-HR expression by lymphocytes 
and decreased numbers of lymphocytes in the intestine (71). Recently, it has been 
reported that RA also regulates the development, expansion, and function of innate 
lymphocytes. RA promotes IL-22 expression by γδT-cells and type 3 innate lymphoid 
cells (ILC3s) through RARα directly binding to promoter regions of the IL-22 gene (72). 
Vitamin A status affects the balance of ILC subsets in the intestine. Spencer et al., 




anti-bacteria and anti-parasite immunity in mucosal tissues. RA also has a significant role 
in the development of ILC3s. RA-RAR signaling is important for lymphoid tissue 
inducer cell (LTi cell) development in the gut tissue of the fetus (74). This is the one of 
the factors that emphasizes the importance of maternal vitamin A on the immunity of 
their offspring. Collectively, RA has significant impacts on the regulation of innate and 
adaptive immunity in mucosal tissues.  
 
1.2.2 Lymphocyte migration program for gut homing 
Lymphocytes circulate in the bloodstream and can migrate to certain tissue sites 
in respond to specific signals such as chemokines (75, 76). Lymphocytes express tissue-
specific chemokine receptors and integrins for directing their migration. The interactions 
between chemokine receptors/integrins and chemokines/adhesion molecules guide 
lymphocytes to migrate to certain tissues sites. The gut homing of lymphocytes is the 
most well established migration program. CCR6, CCR9, CCR10, CD103, and α4β7 are 
known as gut homing receptors (HRs) and these receptors play significant roles in 
migration and localization of lymphocytes to intestinal tissues (70, 71, 77-81). Beyond 
gut HR expression, lymphocytes undergo more sophisticated migration programs to 
migrate to the intestine. The naive T cells can migrate to  secondary lymphoid tissues by 
utilizing CCR7 and CD62L (70, 71). In gut-associated secondary lymphoid tissues such 
as the mesenteric lymph nodes (MLN) and Peyer’s patches (PP), T cells undergo a 
homing receptor switch to change preferential migration from secondary lymphoid 
tissues to intestinal tissue. RA, as an intestinal tissue factor, can induce this homing 




secondary lymphoid tissue receptors, CCR7 and CD62L, but induces expression of gut 
HRs, CCR9 and α4β7. Unlike T cells, innate lymphocytes are not thought to have 
sophisticated migration programs. Instead, they usually upregulate trafficking receptors 
in response to inflammatory signals and then migrate to sites of inflammation (82). 
 
1.2.3 Innate lymphoid cell (ILC) subsets 
ILCs are a recently identified family of heterogeneous innate immune 
lymphocytes. ILCs play important roles in host defense against pathogens and tissue 
inflammation (83, 84). Interestingly, ILCs do not express antigen-specific receptors, but 
they share many functional phenotypes with CD4+ T-cells (84, 85). For example, ILCs 
can produce the cytokines IFN-γ, IL-5, IL-9, IL-13, IL-17A, and IL-22 that are typically 
known as signature cytokines for CD4+ T-cell subsets. ILCs also can express common 
CD4+ T-cell transcription factors, including T-bet, GATA-3, and RORγt, which are 
required for their development and functional activity (86). ILCs are subdivided into 
three groups, based largely on the expression of signature transcription factors and 
effector cytokines. ILC1s require the transcription factor T-bet (Tbx21) and produce IFN-
γ, and as such resemble Th1 cells. ILC1s can induce chronic inflammation in the tissue 
and promote anti-intracellular bacteria immunity (87). ILC2s, which produce IL-5 and 
IL-13, require RORα, GATA-3, and Tcf7 for development in a similar manner as Th2 
cells (88). ILC2s are involved in the regulation of metabolic homeostasis, anti-parasite 
immunity, and allergic diseases (88, 89). ILC2s produce cytokines in response to IL-25 
and IL-33 secreted by epithelial cells and are known to initiate a Th2 response in the lung. 




which mediates gut tissue homeostasis and induces anti-extracellular bacteria immunity 
(90, 91). The functional transcriptional phenotype of ILC3s is similar to that of Th17 
cells. Interestingly, ILCs regulate T-cell responses in mucosal tissues in an antigen-
dependent manner (92). Like professional antigen-presenting cells, ILC2s and ILC3s 
express MHCII to present antigens (90, 93). MHCII-dependent antigen presentation by 
ILCs is critical for the regulation of T-cell homeostasis in the lung and intestine. 
 
1.2.4 Trafficking receptor expression of ILC subsets 
Recent reports revealed that homing receptor expression is required for ILC 
development, migration, and effector function. In this section, we reviewed tissue 
trafficking receptor expression by ILCs during development and maturation. Table 1.1 
shows homing receptor (HR) expression by ILC progenitors, ILC precursors, and mature 
ILCs. ILC progenitors have a broad migration potential for peripheral tissues. BM 
common lymphoid progenitors (CLPs) express CCR7. ILC progenitors such as 
CXCR6+ α-lymphoid progenitor (αLP), and Id2+NFIL+ common helper-like lymphoid 
progenitor (CHILP), Id2+PLZF+ ILCP express α4β7 (87, 94, 95). This is intriguing 
because these receptors are implicated in immune cell migration and cell-cell interaction 
in various peripheral tissues (96). Among ILC precursors in the BM, ILC2Ps express 
integrin α4β7 and CCR9 (88, 97).  
ILCs express tissue-specific but largely subset-independent HRs, and this 
acquisition of HRs is thought to occur during their functional maturation in the periphery. 
Mouse skin ILC2s express CD103 (Itg-αE) and CXCR6 (98). CD103 mediates 




ILC2s in the small intestinal-LP express CCR4, CCR8, CCR9, CXCR4, and CXCR6 (86). 
Thus, the HR profile of gut ILC2s is largely different from that of skin ILC2s, but many 
HRs are shared with Th2 cells. On the other hand, ILC3s express numerous HRs 
reminiscent of Th17 cells. The migration of ILC3s to lymph nodes is regulated by CCR7 
(99). LTi ILC3s migrate from the small intestine to the draining mesenteric lymph nodes 
in a CCR7-dependent manner. Gut ILC3s express CCR9 and α4β7 (97). In addition to 
CCR9 and α4β7, NKp46+ ILC3s express CXCR6 to migrate local site of small intestine 
in respond to CXCL16, which produced by CX3CR1+ myeloid cells (100). CD4+ LTi 
ILC3s express CCR6 and are localized to cryptopatches and isolated lymphoid follicles in 
the gut (101, 102). ILC3s in the small intestine additionally express CCR1, CXCR3, and 
CXCR4, which may promote ILC3 localization and interaction with other cell types for 
effector function (86, 103). 
ILC1s share many HRs with ILC3s. CCR9 and α4β7 are required for optimal 
population and migration of ILC1s to the intestine. They also express CXCR3, CXCR4, 
CCR5, and CXCR6. CCR5 appears to be preferentially expressed by ILC1s among ILCs 
(86). The intestinal intraepithelial compartment is enriched with CD103-expressing 
human ILC1 (104, 105). Overall, NK cells and non-NK ILC1s share many trafficking 
receptors. Both NK cells and ILC1s in the small intestinal lamina propria express CCR5, 
CCR9, CXCR3, CXCR4, and CXCR6 (86). NK cells in the spleen and liver variably 
express CX3CR1, CCR5, CXCR3, and CXCR4. Some NK-cell subsets migrate to lymph 
nodes and promote Th1 responses, a process dependent on CCR7 or CXCR3 (106, 107). 
CXCR4 is important for NK cell retention in the bone marrow, and the sphingosine-1-






Figure 1.1 Roles of SCFAs on the regulation of intestinal immune responses. 
Dietary fibers are converted into SCFAs by bacterial fermentation in the intestine. SCFAs 
regulate immune cell activities through two different pathways. First, SCFAs activate 
GPCR (GPR41, GPR43, and GPR109A) to induce intracellular signaling pathway to 
produce inflammatory mediators. Second, SCFAs transport into cells and regulate 






Figure 1.2 Retinoic acid effects on the regulation of lymphocyte responses. 
Vitamin A is converted into retinoic acid (RA) through CD103+ mucosal dendritic cells. 
RA is known to regulate gut homing and differentiation of adaptive lymphocytes. RA 
induces gut homing receptors by adaptive lymphocytes and promotes regulatory T-cells 










Table 1.1 Trafficking receptor expression by ILC progenitors, ILC precursors, and 
mature ILC subsets in various tissues. 
ILC subsets such as NK, ILC1, ILC2, and ILC3 can be made from a group of progenitor 
cells such as CLP, αLP, CHILP, and ILCP in the bone marrow or from fetal liver 
progenitors. The HRs expressed by human ILCs are enclosed in parentheses (Except for 
ILC progenitors) to distinguish them from the HRs expressed by mouse ILCs. Peripheral 
ILC subsets express a group of HRs, which can be different depending on tissue sites and 
ILC subsets. ND, not determined; Ref, References. 
 
Progenitors Precursors Mature ILCs 
Bone marrow 
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The mucosal surface of the intestinal tract provides a major entry point for food 
antigens, commensal bacterial products, and pathogens (15). The gut immune system 
normally maintains immune tolerance to the harmless antigens but can mount effective 
immune responses upon infection by pathogens. The mechanism(s) that control the 
balanced immunity and immune tolerance in the intestine, however, remain incompletely 
understood. The intestine is densely populated with commensal bacteria which 
metabolize undigested carbohydrate fibers in the colon (120, 121). Evidence is available 
that the gut commensal bacteria produce factors that profoundly affect the immune 
system (122).  
Short chain fatty acids (SCFAs) are the major metabolites of dietary fibers and 
produced from microbial fermentation in the colon (123). SCFAs are volatile fatty acids 
with 1 to 6 carbon atoms and include acetate (C2), propionate (C3), and butyrate (C4) as 
the major SCFAs. Intestinal epithelial cells play significant roles in regulation of 
intestinal immune responses through recognition of antigens and production of various 
immune modulators. And the biological functions of these cells can be readily affected by 




xtensively studied butyrate, have regulatory effects on various aspects of 
epithelial cell biology (25). SCFAs serve as an energy source for epithelial cells and 
regulate intestinal epithelial cell proliferation, differentiation, and apoptosis (124, 125). 
SCFAs are transported into cells through monocarboxylate transporters and solute 
transporters (126). Also, SCFAs activate cells through GPR41 and GPR43. GPR41 and 
GPR43 are expressed highly by gut epithelial cells (127). GPR41 and GPR43 are 
expressed also by adipocytes and implicated in regulation of leptin expression and energy 
balance (13, 128). GPR43 is expressed by phagocytes and controls phagocyte functions 
and tissue inflammation (21, 129). The functions of SCFAs in regulation of inflammatory 
responses and anti-bacterial immunity in the intestine are poorly understood. Also, roles 
of SCFA receptors, GPR41 and GPR43 on the regulation of inflammatory responses in 
the intestine are still unknown. 
Here, we investigated the functions of SCFAs and their receptors in regulation of an 
acute immune response following chemical or pathogenic bacteria infection-induced 
inflammatory immune responses. We report that GPR41 and GPR43 expression in 
intestinal epithelial cells are required for induction of effective inflammatory immune 
responses. SCFAs and their receptors promote acute inflammatory responses in the 
intestine for efficient protection of the host from pathogens. Overall, we provide 
evidences that SCFAs have significant impacts on regulation of anti-bacterial immunity 





2.2 Materials and methods 
 
Animals 
All experiments with animals in this study were approved by the Purdue Animal 
Care and Use Committee. CD45.2 and CD45.1 C57BL/6 mice were from Harlan and 
Jackson Laboratory, respectively. GPR43-/- C57BL/6 mice were from Deltagen (San 
Mateo, CA), and GPR41-/- C57BL/6 mice were described previously (13). All mice were 
maintained at Purdue for at least 2 years before use. Mice were maintained on a regular 
rodent chow (Harlan 2018S Global 18% Protein Rodent Diet). Mice were weaned at 3 
weeks of age.  
 
In vivo studies 
For induction of intestinal inflammation with ethanol and TNBS, mice were fasted 
overnight and received an intrarectal administration of 100 µl of 50% ethanol using a 
round-tip needle. Intestinal inflammation with TNBS was induced as described 
previously (137). Mice were sacrificed one day after ethanol challenge or three days after 
the TNBS challenge. For pathogenic bacterial infection, mice were infected with C. 
rodentium (DBS100). For infection of C2-administered mice, mice were fed with C2 
(sodium acetate, 200 mM, pH 7.5) in drinking water for 4 weeks and infected with C. 
rodentium (1010 CFU/mouse). When indicated, mice were injected i.p. with antibodies 
(50 µg/injection for each antibody) to neutralize IL-6 (MP5-20F3 on day 0 and 2) and 
deplete neutrophils (RB6-8C5 on day -2 and 0). Weight change and stool consistency 




in body weight, signs of illness, and stool scores. Stool consistency scores were measured 
as described previously (23). Briefly, stool scores were measured as follows: 0, normal 
stool; 1, soft stool; 2, diarrhea; 3, diarrhea and anal bleeding. Mice challenged by TNBS 
or C. rodentium were monitored daily for changes in body weight and stool scores. 
Infected mice were monitored for stool C. rodentium burden.  
 
Scoring of the intestinal inflammation 
Histological changes in the distal colon following rectal administration with 50% 
ethanol with or without ethanol and TNBS (Sigma-Aldrich, St. Louis, MO). Colon tissues 
in paraffin were cut into 6 μm-thick sections and stained with hematoxylin and eosin 
(H&E). The sections were semiquantitatively graded on a 0-4 scale based on pathological 
features, including the extent of leukocyte infiltration, crypt elongation/abscess, bowel 
wall thickening, mucosa hyperplasia, and ulceration. 0, no evidence of inflammation; 1, 
low level of leukocyte infiltration in <10% high power fields (hpf), no structural changes 
observed; 2, moderate leukocyte infiltration in 10–25% hpf, crypt elongation, and bowel 
wall thickening; 3, high level of leukocyte infiltration in 25–50% hpf, bowel wall 
thickening and mucosa hyperplasia; and 4, severe leukocyte infiltration in >50% hpf, 
crypt elongation, bowel wall thickening, mucosa hyperplasia, and ulceration. 
 
Assessment of C. rodentium load 
For enumeration of fecal C. rodentium, fecal pellets were collected, weighed, and 
homogenized in sterile PBS. The fecal homogenates were serially diluted and plated in 




Bacterial colony forming units (CFU) were calculated per g of fecal pellet.  For C. 
rodentium in the spleen and liver, organ homogenates were plated on MacConkey agar. 
 
Generation of bone marrow chimeras 
Congenic mouse strains with allergic variants with CD45 (CD45.1 and CD45.2) 
were used for chimeric study. Host mice were exposed to 500 cGy of ionizing radiation 
twice and were reconstituted with 10 million donor bone marrow cells by tail vein 
injection. The mice were kept for 8 weeks for hematopoietic reconstitution and were 
sensitized and administered with TNBS, or infected with C. rodentium. The marrow 
reconstitution efficiency was greater than 95% (based on spleen). 
 
Confocal microscopy 
Frozen and paraffin-embedded tissue sections were prepared at 6-8 μm 
thicknesses. Colon sections were stained respectively with rabbit polyclonal antibodies to 
ZO-1 (Invitrogen) and Phospho-p44/42 MAPK (Erk1/2) (Cell signaling technology). The 
slides were further stained with fluorescently labeled polyclonal anti-rabbit IgG 
antibodies (Invitrogen). Tissue sections were stained with anti-Gr-1 (RB6-8C5) and 
Hoechst 33342 (Invitrogen) when indicated. The fluorescence images were collected with 
a SP5 II laser scanning microscope system (Leica). Colonic paraffin-embedded sections 








Mice were fasted overnight, then received an intragastrical injection of 
fluorescein isothiocyanate (FITC)-conjugated dextran (0.2 mg/g of body weight; average 
MW 3,000-5,000; Sigma-Aldrich) using a round-tip feeding needle. The mice were 
sacrificed 3 hours later, and the FITC-dextran concentration in the plasma was 
determined with a fluorescent microplate reader (excitation at 485 nm and emission at 
535 nm; Biotek Synergy HT). 
  
In vitro culture of colonic epithelial cells 
Lamina propria (LP) cells and colonic ECs (purity > 95% based on CD45- cells) were 
isolated as described previously (138). For expression of GPR41 and GPR43, colonic EC 
(CD326+ cells) were isolated by Miltenyi magnetic beads. Colonic ECs (2×105 cells/well) 
were cultured for 6 days, and C2 (10 mM) or C3 (1 mM) was added during this culture 
period. These cells were further activated with LPS (Sigma-Aldrich; 1 µg/ml) or a 
commensal bacterial antigen (CBA, 20 µg/ml) for 24 h. Alternatively, colonic ECs, 
established for 3 days, were treated with kinase inhibitors (PD98059, U0126, SB203580, 
and SP600125; Enzo Life Sciences, Inc., Farmingdale, NY) and SCFAs for 3 days. 
Concentrations of indicated cytokines in serum and conditioned medium were measured 









Flow cytometry was performed as described previously (138). For neutrophils, tissue 
cells were stained with antibodies to Gr-1 (RB6-8C5) and 7/4 (Ly-6B.2; Serotec). For 
intracellular staining for IL-17 and IFN-γ, T cells were stained first for surface antigens 
and then activated in RPMI 1640 (10% FBS) with PMA (50 ng/ml; Sigma Aldrich), 
ionomycin (1 μM; Sigma Aldrich) and monensin (2 mM; Sigma Aldrich) for 4 h. Then, 
cells were fixed, permeabilized and stained with antibodies to mIL-17A (TC11-18H10.1) 
or mIFN-γ (XMG1.2). For FoxP3+ cells, cells were stained with anti-mFoxP3 (FJK-16s) 
according to the manufacturer's protocol (eBioscience). Stained cells were analyzed with 
FACS Canto II (BD Bioscience). For phosphorylation of ERK and ATF2 in ECs, cells 
were fixed and permeabilized with perm III buffer (BD Bioscience) and stained with 
antibodies to Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) or Phospho-ATF-2 
(Thr71) (Cell signaling). Donkey anti-rabbit IgG-FITC (BioLegend) was used as the 
secondary antibody. Spleen and intestinal lamina propria cells were examined.  
 
Microarray and quantitative, real time PCR 
Colon tissues were frozen in liquid nitrogen and ground using mortar and pestle. 
The array data were analyzed as described and deposited at: 
http://www.ncbi.nlm.nih.gov/geo (GSE36569). qPCR was performed as previously 
described. For bacterial 16S Ribosomal RNA Gene Analysis, total DNA was isolated 
from colon tissues and fecal pellets using QIAamp DNA Stool Mini Kit (Qiagen, 
Valencia, CA). For total eubacteria in tissues, a pair of primers was used to amplify the 




PCR was performed using Maxima SYBR Green/ROX qPCR Master Mix (Thermo 
Scientific, Logan, UT). Tissue-associated bacteria levels based on the Ct values of the 
amplified conserved 16S rRNA gene sequence were normalized with the signal of 
amplified mouse genomic (β-actin) gene. The abundance of specific bacterial groups was 
measured with group-specific 16S rRNA gene primers (synthesized by Integrated DNA 
Technologies). The signals of group-specific 16S rRNA gene were normalized with that 
of the total eubacteria 16S rRNA gene. Primers information is described in Table 2.1. 
 
Statistical analysis 
Student’s t-test, Mann-Whitney test, and One-Way Analysis Of Variance 
(ANOVA) were used to determine significance of the differences between groups. p 

















GPR41 and GPR43 are required for normal level of inflammatory response 
following ethanol-induced breach of the gut barrier 
To gain general idea about immunological function of SCFA receptors, GPR41 
and GPR43 in the induction of inflammatory responses, we injected ethanol into WT, 
GPR41-/-, and GPR43-/- mice to transiently breached the gut barrier function. The ethanol 
challenge induced decrease in the weight of WT mice. However, the GPR41- and 
GPR43-deficient mice showed mild response in weight change to ethanol challenge (Fig. 
2.1A). Also, WT mice had shorter and thicker colon tissue in gross examination than both 
KO mice (Fig. 2.1B). In line with less inflammatory responses in SCFA receptors 
deficiency, both KO mice showed reduced leukocyte infiltration in the mucosa and 
submucosa, thus they have reduced histology scores (Fig. 2.2). The ethanol treatment 
induced infiltration of neutrophils within the colon tissue. In this regard, infiltration of 
neutrophils in the colonic lamina propria was abnormally low in the SCFA-receptor KO 
mice compared to WT mice (Fig. 2.3A). Immunohistochemistry (IHC) revealed that only 
WT mice had significantly increased Gr-1+ cells in colon tissue following ethanol 
challenge (Fig. 2.3B). Inflammation induces elevation of gut permeability and this leads 
to facilitated antigen recognition by antigen presenting cells, resulting in further 
inflammation. We investigated gut permeability changes during inflammation. IHC 
revealed that GPR41-/- and GPR43-/- mice maintain ZO-1 expression following the 
ethanol treatment but WT mice lost ZO-1 expression in colon tissue (Fig. 2.3B). We 




the GPR41 and GPR43 KO mice showed mild gut permeability changes (Fig. 2.4A). In 
line with smaller gut permeability change in GPR41-/- and GPR43-/- mice, they had 
smaller increases in tissue bacteria compared to WT mice (Fig. 2.4B). We performed 
microarray for examination of inflammatory responses-related genes expression regulated 
by SCFA receptors. Interestingly, the patterns of gene expression in colon tissues of 
GPR41- and GPR43-deficient mice are similar (Fig. 2.5A). Many genes, including 
chemokines, inflammatory cytokines, and metalloproteinases induced in WT mice were 
not induced in the two SCFA-receptor KO mice (Fig. 2.5A, B). These findings also were 
confirmed by qPCR (Fig. 2.6). Results indicate that SCFA receptors, GPR41 and GPR43, 
positively regulate inflammatory gene expression after immune challenge. 
  
GPR41 and GPR43 are necessary for an efficient induction of inflammatory 
response to TNBS 
We further examined the inflammatory responses to TNBS in WT, GPR41, and 
GPR43 KO mice. Like ethanol treatment, TNBS treatment decreased BW in WT mice by 
20% but, the same challenge induced a smaller level of BW loss in GPR41 and GPR43 
KO mice. Only WT, but not the KO mice, had increased stool scores on day 2 (Fig. 2.7A 
and B). Colon length of WT mice was significantly shorter than those of both KO mice 
(Fig. 2.7C). Also, the distal colon of both KO mice strains had less leukocyte infiltration, 
mucosa hyperplasia, and tissue damage after TNBS challenge (Fig. 2.8). Notably, IL-6 
levels are lower in both SCFA receptor-deficient mice compared to those of WT mice 
(Fig. 2.9). Induction of Th1 (CD4+IFN-γ+ cells)-associated genes (IL-12, IFN-γ, and T-




frequency of Th1 cells (CD4+IFN-γ+) was decreased in the small intestine, colon, and 
MLN of the KO mice (Fig. 2.10B). Moreover, induction of neutrophil responses 
including chemoattractants, CXCL1, CXCL2, and CCL2 expression in the colon was 
abnormally low in GPR41-/- and GPR43-/- mice (Fig. 2.11A and B). These results indicate 
that SCFA receptors play positive roles in mounting the acute inflammatory response to 
TNBS. 
 
GPR41- and GPR43-deficient mice display delayed pathogen clearance 
From abnormal induction of inflammatory responses in GPR41- and GPR43-
deficient conditions, we assumed that GPR41 and GPR43 play a significant role in 
control pathogenic bacteria in the intestine. We utilized a C. rodentium infection model to 
determine the role of SCFA receptors in mounting immune responses to bacterial 
pathogens. As expected, GPR41-/- and GPR43-/- mice were more susceptible to infection 
than WT mice based on weight changes and stool consistency scores (Fig. 2.12A and B). 
Both KO mice showed a delayed clearance of C. rodentium from the intestinal tissue in 
late stage of infection (Fig. 2.12C). Both KO mice had more detectable bacteria in 
peripheral organs such as liver and spleen than WT mice, indicating increased 
translocation of the pathogenic bacteria (Fig. 2.12C). Both KO mice had low responses in 
neutrophil recruitment, and frequencies of effector T cells in the colon (Fig. 2.13A and B). 
We found that the expression kinetics of inflammatory cytokines were delayed in both 
KO mice by 1-2 weeks (Fig. 2.14A and B). Regarding the gut permeability, GPR41 and 
GPR43 KO mice showed a delayed kinetics in the change of gut permeability and 




differences on gut permeability and tight junction protein (ZO-1) expression between WT 
and SCFA receptor-deficient mice (Fig. 2.16A and B). In addition, C2 administration had 
no impacts on the gut permeability in WT mice. These results suggest that differences in 
gut permeability are mainly mediated by different levels of inflammation after immune 
challenge. 
 
Acetate (C2) administration facilitates anti-pathogenic bacterial immunity  
in the intestine 
Next, we investigated the role of SCFAs on the anti-pathogenic bacterial 
immunity in the gut. We administered C2 (100 mM) to mice and examined immune 
responses and bacterial clearance in the gut. In infection studies, C2-treated mice were 
more resistant to infection based on BW changes and stool consistency scores compared 
to control mice (Fig. 2.17A). Also, C2-fed mice had lower intestinal C. rodentium loads 
(Fig. 2.17B). Regarding the immune responses to infection, C2-fed mice showed 
accelerated kinetics of inflammatory cytokine and chemokine expression (Fig. 2.18A and 
B). In line with this, C2 administration increased recruitment of neutrophils and Th17 
(CD4+IL-17A+) cells in the cecum (Fig. 2.19A and B). C2 administration also facilitated 
a change in gut permeability (Fig. 2.19C). Thus, C2 administration accelerated the overall 
immune response during the infection. To demonstrate the importance of facilitated 
immune responses by SCFA administration, we neutralized or depleted IL-6 and 
neutrophils in animals fed control or C2 water during infection. As expected, antibody 
injection delayed immune responses, including of IL-6-Th17 axis and CXCL1/2-




(Fig. 2.18A and B). This indicates the important roles of IL-6 and neutrophils in 
induction of the anti-pathogenic bacterial immunity (Fig. 2.19A and B). Notably, the C2 
effects on immunity were abolished by the antibody treatments. We also tested if 
antibody injection affects gut permeability during infection. As expected, antibody 
injection delayed increase of gut permeability at an early time points (Fig. 2.19C). At 
later time points, however, a greater change in gut permeability occurred in the antibody-
injected animals (Fig. 2.19C). We also examined the levels of seven bacterial groups in 
the gut of GPR41-/- and GPR43-/- mice to determine whether SCFA receptor deficiency 
may affect the gut microbiota in the gut. There was no significant change in the gut 
microbiota profile (Fig. 2.20).  
 
Identification of potential immune cell types involved in SCFA receptor-mediated 
anti-bacterial immune responses 
To determine the relative contribution of SCFA receptors expressed by marrow 
versus non-marrow-derived cells in immune responses, we prepared bone marrow-
chimeras with WT recipients and GPR41-/- or GPR43-/- marrow donors or vice versa. 
Clinical symptom and immune responses in chimera were examined following C. 
rodentium infection (Fig. 2.21). Host mice (WT) reconstituted with WT or KO marrow 
showed comparable clinical symptoms and bacterial clearance. In contrast, the KO host, 
reconstituted with WT marrow, lost weight significantly, and higher stool scores and 
bacteria load (Fig. 2.21A-C). In line with the delayed clearance of C. rodentium, 
frequencies of Th17 (CD4+IL-17A+) cells and neutrophils were lower in the colon of both 




experiments, we concluded that expression of SCFA receptors by non-hematopoietic 
cells play significant roles in anti-bacterial immunity compared to those by hematopoietic 
cells. We also confirmed this finding in the TNBS-induced colitis model (Fig. 2.23). In 
line with BM chimera studies, both GPR41 and GPR43 mRNAs were highly expressed 
by CD326+ (EpCAM) epithelial cells (Fig. 2.24). 
 
SCFAs-receptors axis activates production of chemokines and cytokines in colonic 
epithelial cells in a MEK-ERK-dependent manner 
High expression of SCFAs receptors in epithelial cells and the BM chimera study 
promoted us to investigated role of SCFAs and their receptors on the regulation of 
immunological function of intestinal epithelial cells (ECs). First, we compared 
production of cytokines and chemokines between control and SCFA-treated cultured 
primary epithelial cells. The expression of IL-6, CXCL1, and CXCL10 in colonic 
epithelial cell cultures was increased by C2 or C3 treatment. This induction was 
completely abolished when cells were pretreated with pertussis toxin (PTX), which is an 
inhibitor of G0/i-coupled receptors such as GPR41 and GPR43 (Fig. 2.25). The ECs 
isolated from GPR41-/- or GPR43-/- mice were largely unresponsive to C2 or C3 in 
expression of the cytokines and chemokines beyond basal levels (Fig. 2.26A and B). 
There results suggest that GPR41 and GPR43 are involved in SCFA-mediated 
inflammatory molecules production by ECs. We studied the intracellular pathways 
important for SCFA-dependent expression of inflammatory mediators. As the 
intracellular mechanism, we identified that SCFAs activate ERK signaling pathway in 




in ERK activation to SCFA treatment (Fig. 2.27), suggesting that ERK activation is 
induced by the SCFA signals through GPR41 and GPR43. We also confirmed that ERK 
inhibitors PD98059 (a MEK1 inhibitor) and U0126 (a MEK1/2 inhibitor) suppressed 
ERK activation in ECs (Fig. 2.27). In addition, these inhibitors suppressed SCFA-
induced IL-6, CXCL1, and CXCL2 expression (Fig. 2.28 and Fig. 2.29). This ERK 
activation was suppressed by two inhibitors of ERK: PD98059 (a MEK1 inhibitor) and 
U0126 (a MEK1/2 inhibitor) (Fig. 2.28). These inhibitors also suppressed the expression 
of IL-6, CXCL1 and CXCL2 induced in response to C2 or C3 (Fig. 2.29). Also, p38 
MAPK is implicated in the SCFA receptor signaling in a breast cancer cell line. 
SB203508 (a MAPK inhibitor) was less effective than the ERK inhibitors but still 
suppressive at a high concentration However, a c-Jun N-terminal kinases/JNK inhibitor, 
SP600125, was ineffective (Fig. 2.28 and Fig. 2.29). IHC revealed that in vivo 
administration of C2 increased activation of ERK in colons of WT, but not GPR41 or 
GPR43 KO mice after C. rodentium infection (Fig. 2.30). We also examined downstream 
molecules activation of ERK. Activating transcription factor 2 (ATF2) is involved in 
expression of inflammatory cytokines and chemokines. SCFAs induce transcription 











We investigated the roles of SCFAs and their receptors in the regulation of 
intestinal immunity. Defective immune responses including changes in gut permeability, 
expression of inflammatory mediators, leukocyte infiltration, and tissue inflammation 
were detected in the mice deficient in GPR41 or GPR43 following immune challenge. 
Also, expression of GPR41 and GPR43 by ECs is required for mounting effective 
inflammatory responses including effector T-cell responses and neutrophil accumulation 
in inflamed tissue. Our results establish important roles of SCFA signaling in the 
induction of immune responses through activation of epithelial cells. 
 SCFAs are highly enriched in the colon tissue, and their receptors, are highly 
expressed by intestinal ECs. It has been reported that butyrate can decrease the tight 
junction permeability (139, 140). Unexpectedly, ethanol challenge induces a transient 
increase in mucosal permeability in the intestine and triggers gut bacterial entrance into 
the lamina propria area in WT mice. However, GPR41-/- or GPR43-/- mice had 
significantly milder changes in gut permeability compared to WT mice. Moreover, 
expression of the tight junction protein ZO-1 was better maintained in the SCFA 
receptor-deficient mice than WT mice following the ethanol treatment. But, tight junction 
protein expression is comparable in WT and both KO mice without immune challenge. 
These results suggest that activation of the SCFA receptors functions to increase the gut 
epithelial permeability, with a probably outcome of mounting an effective immune 




Neutrophils accumulate in the intestine during inflammatory responses, and 
chemoattractants including CXCL1 and CXCL2 are major players in recruiting 
leukocytes (141). Mixed conclusions regarding the roles of SCFAs in regulation of gut 
inflammation have been reported. SCFA administration increased gut expression of 
inflammatory cytokines in some studies (142). Others reported that SCFAs, especially 
butyrate, have an anti-inflammatory role in gut inflammation (143). Recently, 
contradictory results on the impact of GPR43 on DSS-induced colitis have been reported 
(21, 22). Thus, the function of SCFAs and GPR43 in regulation of inflammation in the 
intestine remains inconclusive. Our results demonstrated that SCFA receptor-deficient 
mice displayed hypo-inflammation following the ethanol or TNBS treatment. In line with 
the positive roles of SCFA receptors in mediating inflammation, induction of major 
chemokines, such as CXCL1 and CXCL2, and inflammatory cytokines, such as IL-1β, 
IL-6, and IL-12, in the colon was significantly lower in GPR41-/- and GPR43-/- mice 
compared to WT mice. Collectively, SCFAs receptors play a positive role in induction of 
inflammatory responses.  
  With C. rodentium infection model, we examined anti-bacterial immunity in 
SCFA-treated mice or SCFA receptor-deficient mice. Interestingly, we found that both 
KO mice showed delayed clearance of pathogenic bacteria in the intestine. In line with 
this, both KO mice failed to induce the acute inflammatory response post infection. 
Acetate (C2) administration accelerated anti-bacterial immunity based on clearance of the 
pathogen and induction of inflammatory molecules such as cytokines and chemokines. 
These results suggest that SCFA-receptor signaling has a significant role in anti-bacterial 




SCFA receptors are highly expressed by epithelial cells. Thus, these receptors are 
more likely play a significant role in regulation of intestinal immune response through 
epithelial cells. The chimera studies indicate that the GPR41 and GPR43 expressed by the 
non-marrow-derived cells have significantly larger impacts than marrow-derived cells in 
mediating tissue inflammation, mounting a T-cell response, and generating neutrophil 
accumulation in the TNBS-induced inflammation model and C. rodentium infection 
model. This result is also supported by our in vitro study with intestinal ECs that 
indicates that SCFA receptors are required for SCFA-mediating inflammatory mediator 
production by colonic ECs. These data suggests the SCFA-receptor axis in epithelial cells 
has a significant impact on effective induction of anti-bacterial immunity. 
As an intracellular mechanism, we found that activation of MEK-ERK and p38 
MAPK pathways and the ATF2 transcription factor are required for normal expression of 
inflammatory cytokines and chemokines by ECs in response to SCFAs. In summary, gut 
microbiota-produced SCFAs activate SCFA receptors on colonic ECs, which leads to 










2.5 Summary and future directions 
 
We identified SCFA have positive function on induction of inflammatory responses 
followed by chemical or pathogen challenges. SCFAs activate GPR41 and GPR43 on 
intestinal epithelial cells to induce production of inflammatory mediators. Underlying 
mechanism is that SCFA-receptors axis activate ERK signaling to induce gene 
expressions of inflammatory mediators. SCFA-receptor-mediated inflammatory 
responses have implicated in anti-bacterial immunity in the intestine. The efficient anti-
bacterial immunity contributes the maintenance of gut homeostasis in the steady state. 
Therefore there is a possibility that SCFAs potentially have long term effects on the 
regulation of immune homeostasis through multiple immune cell types. Thus, effects of 
dietary fibers or SCFAs on the regulation of inflammation-associated tumorigenesis need 
to be studied. And impacts of SCFAs on the regulation of other immune cells such as B 
cells, which are important for anti-bacterial immunity and inflammation are need to be 














Figure 2.1 Hypo-inflammatory responses in GPR41-/- and GPR43-/- mice after 
ethanol-induced breach of intestinal barrier function. 
Clinical symptom of WT, GPR41-, and GPR43-deficient mice following ethanol 
challenge. Weight change (A) and gross appearance, and colon length (B) in mice 
following the ethanol treatment. Mice were treated by intra-rectal injection of 50% 
ethanol. All of the data were obtained at 24 h after ethanol treatment. Pooled data from 
three independent experiments are shown. Significant differences (p<0.05) from 












Figure 2.2 Mild histological changes in GPR41-/- and GPR43-/- mice following rectal 
administration of ethanol. 
Histological changes in the distal colon of WT, GPR41-/-, and GPR43-/- mice following 
rectal administration of 50% ethanol. Colon tissues in paraffin were stained with 
hematoxylin and eosin (H&E). The sections were graded on a 0-4 scale based on 
pathological features, including the extent of leukocyte infiltration, crypt 
elongation/abscess, bowel wall thickening, mucosa hyperplasia, and ulceration. 0, no 
evidence of inflammation; 1, low level of leukocyte infiltration in <10% high power 
fields (hpf), no structural changes observed; 2, moderate leukocyte infiltration in 10–25% 
hpf, crypt elongation, and bowel wall thickening; 3, high level of leukocyte infiltration in 
25–50% hpf, bowel wall thickening and mucosa hyperplasia; and 4, severe leukocyte 
infiltration in >50% hpf, crypt elongation, bowel wall thickening, mucosa hyperplasia, 







Figure 2.3 Reduced neutrophil infiltration in colon tissue following ethanol-induced 
breach of intestinal barrier function in GPR41-/- and GPR43-/- mice. 
 
 (A) Neutrophil infiltration in the colon following the ethanol treatment. Neutrophil 
frequency (%) among colonic lamina propria cells is shown. Neutrophils were stained by 
anti-Gr-1 and anti-7/4 antibody and data were acquired by flow cytometry. (B) 
Expression of ZO-1 and GR-1 in the colon during the inflammation was examined by 
IHC. For immunofluorescence staining, 6 μm-thick frozen and paraffin colon sections 
were stained respectively with rabbit polyclonal antibodies to ZO-1 and anti-Gr-1 and 












Figure 2.4 Reduced gut permeability and tissue bacteria infiltration in colon tissue 
following ethanol-induced breach of intestinal barrier function in GPR41-/- and 
GPR43-/- mice. 
 
(A) The gut barrier function was determined based on FITC-dextran leakage into the 
blood following the ethanol treatment (n=10-12/group). For measurement of gut 
permeability, mice fasted overnight, received intragastrically with fluorescein 
isothiocyanate (FITC)-conjugated dextran. The mice were sacrificed 3 h later, and the 
FITC-dextran concentration in the plasma was determined with a fluorescent microplate 
reader. (B) Levels of colon tissue-associated commensal bacteria following the ethanol 
treatment (n=10-13/group). Bacterial 16S rRNA gene levels in the colon tissue were 
examined by qPCR for a conserved region of the gene. All of the data were obtained at 
24 h after ETOH treatment. Pooled data from three independent experiments are shown. 








Figure 2.5 Defective induction of inflammation-associated genes in SCFA receptors-
deficient mice following ethanol-induced breach of intestinal barrier function. 
(A) Genes differentially expressed in the colon tissues of WT versus SCFA-receptor KO 
mice following the ethanol treatment. Microarray data are shown in a multi-plot format 
showing gene expression differences between WT and KO mice. (B) Treeviews of 







Figure 2.6 Abnormally low expressions of inflammatory genes in GPR41-/- and 
GPR43-/- mice following ethanol-induced breach of intestinal barrier function. 
qPCR analysis of selected genes for distal colon tissues. All of the data were obtained 
from colon tissues from WT, GPR41-/-, and GPR43-/- mice at 24 h after ethanol treatment. 
Pooled data from three independent experiments are shown. Significant differences 






Figure 2.7 Abnormally low immune responses to TNBS in SCFA receptors-KO mice. 
Weight change (A), stool consistency scores (B), colon length (C) following the TNBS 
treatment.  Mice were sacrificed on 3 day post TNBS injection. Stool consistency scores 
were measured as follows: 0, normal stool; 1, soft stool; 2, diarrhea; 3, diarrhea and anal 
bleeding. Weight change and stool scores were monitored during experimental period. 
Mice were sacrificed three days after the TNBS rectal administration and measured colon 
length. Combined (n=12-30/group) or representative data from 4 independent 
experiments are shown. Significant differences (p<0.05) from untreated WT mice* or 






Figure 2.8 GPR41-/- and GPR43-/- mice were less susceptible to TNBS-induced 
inflammation. 
Histological changes in the distal colon following rectal administration of TNBS. Colon 
tissues in paraffin were stained with H&E. The sections were graded on a 0-4 scale based 
on pathological features, including the extent of leukocyte infiltration, crypt 
elongation/abscess, bowel wall thickening, mucosa hyperplasia, and ulceration. 0, no 
evidence of inflammation; 1, low level of leukocyte infiltration in <10% high power 
fields (hpf), no structural changes observed; 2, moderate leukocyte infiltration in 10–25% 
hpf, crypt elongation, and bowel wall thickening; 3, high level of leukocyte infiltration in 
25–50% hpf, bowel wall thickening and mucosa hyperplasia; and 4, severe leukocyte 
infiltration in >50% hpf, crypt elongation, bowel wall thickening, mucosa hyperplasia, 








Figure 2.9 Abnormally low IL-6 production in GPR41-/- and GPR43-/- mice followed 
by TNBS challenge. 
Levels of IL-6 in the blood or conditioned media of colonic ECs prepared from TNBS-
treated mice. The concentration of IL-6 was examined by ELISA. Mice were sacrificed 
three days after the TNBS rectal administration. Blood was collected for measurement of 
serum IL-6 concentration. Colonic epithelial cells were isolated from WT, GPR41-/-, and 
GPR43-/- mic and cultured in the presence of LPS for stimulation. Conditioned media of 
colonic ECs were harvested for ELISA assay. Significant differences (p<0.05) from 







Figure 2.10 Defective cytokine and T cell responses to TNBS in the gut of GPR41-/- 
and GPR43-/- mice. 
(A) Expression of signature genes for Th1, Th17 and Tregs in the distal colon. qPCR was 
performed for indicated genes. (B) Frequencies of Th1 (CD4+IFN-γ+ cells), Th17 
(CD4+IL-17A+ cells), and Tregs (CD4+FoxP3+ cells), in the intestinal LP and MLN. Flow 
cytometry was performed for examination of T-cell subset frequencies. Percentages of 
CD4+ T-cells are shown. All of the data were obtained on day 3 following the TNBS 
treatment. Pooled data obtained from 5 independent experiments are shown. Significant 






Figure 2.11 Defective chemokine expression and neutrophil recruitment in GPR41-/- 
and GPR43-/- mice following TNBS administration. 
(A) Infiltration of phagocytes in the large intestinal lamina propria. Frequencies of Gr-1+ 
cells were examined by flow cytometry. (B) Expression of chemokines in the distal colon. 
qPCR was performed. Values were normalized to β-actin. All of the data were obtained 
on day 3 following TNBS treatment. Combined (n=12-30/group) or representative data 
from 4 independent experiments are shown. Significant differences (p<0.05) from 









Figure 2.12 Increased susceptibility of GPR41-/- and GPR43-/- mice to C. rodentium 
infection. 
(A) Weight change following C. rodentium infection. (B) Stool consistency scores. Stool 
consistency scores were measured as follows: 0, normal stool; 1, soft stool; 2, diarrhea; 3, 
diarrhea and anal bleeding. (C) C. rodentium loads (colony forming units (CFU) per gram 
of feces or tissue) in feces and indicated organs. Bacterial CFU were calculated per g of 
fecal pellet.  For C. rodentium in the spleen and liver, organ homogenates were plated on 
MacConkey agar. Significant differences (P < 0.05) between WT and GPR41 KO mice* 







Figure 2.13 Delayed immune responses of GPR41-/- and GPR43-/- mice to  
C. rodentium infection. 
(A) Neutrophil infiltration in the colon during infection. Gr-1+ cells were examined. Mice 
were sacrificed at indicated time pointes and colonic neutrophil frequencies were 
examined by flow cytometry. (B) Th1 (CD4+IFN-γ+ cells) and Th17 (CD4+IL-17A+ cells) 
frequencies in the colon at 2 weeks post infection. Percentages of CD4+ T-cells are 
shown. Flow cytometry was performed for panel A and B. *Significant differences 







Figure 2.14 Delayed induction of inflammatory cytokines and chemokines in  
GPR41-/- and GPR43-/- mice during C. rodentium infection. 
(A) Expression of pro-inflammatory cytokines in the cecum (n=13-15/group). (B) 
Expression of CXCL1 and CXCL2 in the cecum (n=10-12/group). WT, GPR41-/-, and 
GPR43-/- mice were sacrificed for examination of kinetics of inflammatory mediators 
expression in cecum tissues. qPCR was performed. Combined data of 3 independent 
experiments are shown. Significant differences (P < 0.05) between WT and GPR41 KO 











Figure 2.15 Delayed gut permeability changes of GPR41-/- and GPR43-/- mice to  
C. rodentium infection. 
(A) Gut permeability change and (B) tissue-associated eubacteria following infection.  
For measurement of gut permeability, mice fasted overnight, received intragastrically 
with fluorescein isothiocyanate (FITC)-conjugated dextran. And mice were sacrificed 3 h 
later. Tissue-associated eubacteria levels based on the Ct values of the amplified 
conserved 16S rRNA gene sequence were normalized with the signal of the amplified 
mouse genomic β-actin gene in each sample. Pooled data obtained from 3 independent 
experiments are shown (4-5/group). Significant differences (P < 0.05) between WT and 









Figure 2.16 GPR41 and GPR43 do not affect gut permeability in the absence of 
immunological challenges. 
Gut permeability (A) and expression of tight junction protein genes were examined by 
qPCR (B) in unchallenged WT, GPR41-/-, and GPR43-/- mice. For measurement of gut 
permeability, mice fasted overnight, received intragastrically with fluorescein 
isothiocyanate (FITC)-conjugated dextran. And mice were sacrificed 3 h later. For 
examination of tight junction protein expressions, colon tissues were harvested from WT, 
100mM C2 fed WT, and receptor KO mice. qPCR was performed. Pooled data obtained 









Figure 2.17 C2 administration accelerates the immune response to infection. 
(A) Weight change and stool consistency scores of WT and C2-fed mice following C. 
rodentium infection. Stool consistency scores were measured as follows: 0, normal stool; 
1, soft stool; 2, diarrhea; 3, diarrhea and anal bleeding. (B) Fecal C. rodentium load. 
Pooled data obtained from 3 independent experiments are shown (n=10-15/group). WT 
and C2-fed mice were infected with C. rodentium. When indicated, mice were injected 
i.p. with antibodies to neutralize IL-6 (on day 0 and 2) and deplete neutrophils (on day -2 







Figure 2.18 C2 administration promotes chemokine and cytokine expression in 
colon tissue to C. rodentium infection. 
Expression of neutrophil chemoattractants, CXCL1 and CXCL2 (A) and expression of IL-
6 (B). Pooled data obtained from 3 independent experiments are shown (n=10-15/group. 
WT and 100mM C2-fed mice were infected by C. rodentium. When indicated, mice were 
injected i.p. with antibodies to neutralize IL-6 (on day 0 and 2) and deplete neutrophils 








Figure 2.19 C2 administration accelerates immune cell responses and gut 
permeability changes followed by infection. 
(A) Neutrophils (Gr-1+) in colon. (B) Th17 (CD4+IL-17A+) cells in the colon. Relative 
values are shown by normalized values to untreated mice. (C) Gut permeability change. 
Some mice were injected twice with antibodies to neutralize IL-6 (day 0 and 2) and 
deplete neutrophils (day -2 and 0). WT and C2-fed mice were infected by C. rodentium. 
When indicated, mice were injected i.p. with antibodies to neutralize IL-6 (on day 0 and 2) 
and deplete neutrophils (on day -2 and 0). Pooled data obtained from 3 independent 
experiments are shown (n=10-15/group). Significant differences (P < 0.05) between WT 






Figure 2.20 No significant changes in commensal bacteria in the gut of  
GPR41-/- or GPR43-/- mice. 
The levels of major bacterial groups in the gut were analyzed by qPCR examination of 
the 16S rRNA gene isolated from the stool of wild-type, GPR41-/-, and GPR43-/- (n = 8-9 
for each group) mice using the primers listed in Table 2.1. The copy numbers of 16S 
rRNA genes for specific bacterial groups were normalized by that of the total eubacteria. 









Figure 2.21 Differential roles of the SCFA receptors expressed by non-bone marrow 
versus marrow-derived cells in promoting the immune response to C. rodentium. 
(A) Weight change following C. rodentium infection in bone marrow chimera mice. (B) 
Stool consistency scores. Stool consistency scores were measured as follows: 0, normal 
stool; 1, soft stool; 2, diarrhea; 3, diarrhea and anal bleeding. (C) Fecal C. rodentium load. 
For generating chimeras, irradiated recipient mice were reconstituted with donor marrow 
cells. The mice were kept for 8 weeks for hematopoietic reconstitution and were 







Figure 2.22 Differential roles of the SCFA receptors expressed by non-bone marrow 
versus marrow-derived cells in effector T cell and neutrophil responses to C. 
rodentium. 
(A) Th17 (CD4+IL-17A+) cells in the colon. (B) Infiltration of the colon by neutrophils 
(Gr-1+). Chimera mice were infected at 8 weeks after the bone marrow-transfer 
(donorhost). Flow cytometry was performed for panel A and B. Pooled data (8-10 
mice/group) obtained from 2-3 independent experiments are shown. Significant 






Figure 2.23 GPR41 and GPR43 are highly expressed by intestinal epithelial cells. 
Expression of GPR41 and GPR43 mRNA by Gr-1+ neutrophils, CD326+ ECs, CD19+ B 
cells, and CD4+ T cells was examined by qPCR. Both CD19+ B cells and CD4+ T cells 
were isolated from spleen. CD326+ ECs were isolated from colon. Gr-1+ neutrophils were 












Figure 2.24 Comparison of the roles of SCFA receptors expressed by non-BM 
versus BM-derived cells in mediating the inflammatory response to TNBS. 
(A) Weight change in marrow-transferred mice (n=10-23/group). (B) Stool consistency 
scores. Stool consistency scores were measured as follows: 0, normal stool; 1, soft stool; 
2, diarrhea; 3, diarrhea and anal bleeding. (C) Gross appearance and length of the colon. 
(D) Infiltration of the colon by neutrophils (Gr-1+ cells). Frequency of neutrophils in 
untreated-WT mice is shown. (E) Th1 (CD4+IFN-γ+) frequency in the colon. All of the 
data were obtained on day 3 following TNBS treatment. Pooled data obtained from three 
independent experiments are shown. Significant differences from WTWT mice* or 






Figure 2.25 SCFA-dependent expression of IL-6 and chemokines by colonic ECs 
was suppressed by pertussis toxin. 
Expression of IL-6, CXCL1, and CXCL10 by ECs in response to SCFAs and bacterial 
products (LPS or commensal bacterial extract) was examined with qPCR. ECs, 
established for 3 days, were treated with pertussis toxin (PTX, FL; 0.1 μg/ml) for 1 h 
before treatment with the SCFAs for 6 days. The cells were then treated with LPS (1 
μg/ml) or commensal bacterial extract (20 μg/ml) for 24 h. Pooled data from three 
independent experiments (n=3) are shown. *Significant differences from the untreated 






Figure 2.26 SCFA-dependent expression of inflammatory chemokines and cytokines 
is dependent on epithelial GPR41 and GPR43. 
(A) Production of inflammatory cytokines by WT, GPR41-/-, and GPR43-/- colonic ECs 
pre-treated with SCFAs and LPS. (B) Expression of chemokines by colonic ECs in 
response to SCFAs and LPS. Colonic ECs were cultured for 6 days, and C2 (10 mM) or 
C3 (1 mM) was added during this culture period. These cells were further activated with 
lipopolysaccharide (LPS; 1 µg/ml) or a commensal bacterial extract (20 µg/ml) for 24 






Figure 2.27 SCFAs activate MEK-ERK pathway in epithelial cells in a GPR41- and 
GPR43-dependent manner. 
WT, GPR41, or GPR43 KO ECs were cultured with C2 or C3 in the presence or absence 
of MEK-ERK pathway inhibitor, PD98059 or U0126 and phosphorylation of ERK were 
examined by flow cytometry. Colonic ECs, established for 3 days, were treated with 
kinase inhibitors and SCFAs for 3 days. MEK1 inhibitor (PD98059) and MEK1/2 








Figure 2.28 SCFA-induced expression of the inflammatory cytokine IL-6 is 
dependent on the MEK-ERK pathway in epithelial cells. 
Effects of signaling molecule inhibitors on SCFA-dependent expression of IL-6 were 
examined. Colonic ECs, established for 3 days, were treated with kinase inhibitors and 
SCFAs for 3 days. qPCR was performed for examination of IL-6 expression. MAPK 
inhibitor (SB203508), c-Jun N-terminal kinases/JNK inhibitor (SP600125), MEK1 
inhibitor (PD98059), and MEK1/2 inhibitor (U0126) were used. Significant differences 






Figure 2.29 Effects of signaling molecule inhibitors on SCFA-dependent expression 
of neutrophil-attracting chemokines by epithelial cells. 
ECs, established for 3 days, were treated with inhibitors and SCFAs for 6 days. The cells 
were then treated with LPS (1 μg/ml) for 24 h before qPCR analysis of CXCL1 (A) and 
CXCL2 (B). MAPK inhibitor (SB203508), c-Jun N-terminal kinases/JNK inhibitor 
(SP600125), MEK1 inhibitor (PD98059), and MEK1/2 inhibitor (U0126) Pooled data 
obtained from three independent experiments (n=3) are shown. *Significant differences 






Figure 2.30 Defective SCFA-induced phosphorylation of ERK in SCFA receptor-
deficient mice after infection with C. rodentium. 
ERK expressions by colon tissues of WT, GPR41-/-, and GPR43-/- mice at 5 days after 
infection with C. rodentium were examined by IHC. WT, GPR41-/-, and GPR43-/- mice 
fed regular water or C2 (100 mM) water before initiation of infection study. For 
immunofluorescence staining, frozen colon sections were stained respectively with 






Figure 2.31 SCFAs induce ATF2 activation in colonic epithelial cells in a GPR41- 
and GPR43-dependent manner. 
Phosphorylation of ATF2 in WT, GPR41-/-, and GPR43-/- ECs were examined by flow 
cytometry. Colonic ECs, established for 3 days, were treated with kinase inhibitors and 
SCFAs for 3 days. Pooled data obtained from three independent experiments (n=3) are 








Table 2.1 Primers used in this study (Chapter 2) 
Quantitative real time PCR (qPCR) for mouse genes was performed. The abundance of 
specific bacterial groups was measured with group-specific 16S rRNA gene primers. The 
signals of group-specific 16S rRNA gene were normalized with that of the total eubacteria 
16S rRNA gene in each sample. *Gene accession numbers. 
Gene (mouse) Forward Reverse References* 
IL17A GAC TCT CCA CCG CAATG CGG GTC TCT GTT TAG GCT NM_010552.3 
RoRγt AGC CAC TGC ATT CCC AGT TTC T TGA AAG CCG CTT GGC AAA CT NM_011281.3 
IFNγ AGA CAA TCA GGC CAT CAG CA CGA ATC AGC AGC GAC TCC TTT NM_008337.4 
T-bet ATG CCG CTG AAT TGG AAG GT  ACC TCG CAG AAA GCC ATG AAG T NM_019507.2 
FoxP3 CAG CTG CCT ACA GTG CCC CTA G CAT TTG CCA GCA GTG GGT AG NM_054039.2 
IL-6 CTG GTC TTC TGG AGT ACC ATA GC TGC CGA GTA GAT CTC AAA GTG 
AC 
NM_031168.2 
IL-12 CTA GGA TCG GAC CCT GCA GG CTA GGA TCG GAC CCT GCA GG NM_008354.2 
CCL2 GTT GGC TCA GCC AGA TGC A AGC CTA CTC ATT GGG ATC ATC 
TTG 
NM_000882.3 
CCL5 TCA CCA TCA TCC TCA CTG C TGA ACC CAC TTC TTC TCT GG NM_013653.3 
CXCL1 CGT CGC TTC TCT GTG CA TGG GGA GAC CTT TTA GCA NM_008176.3 
CXCL2 AAC CAC CGA GCT ACA GG CCT TTC GAG GTC AGT TAG C NM_009140.2 
CXCL10 GGT CTG AGT GGG ACT CAA GG TTT GGC TAA ACG CTT TCA TT NM_021274.2 
CXCL13 GCA GAA TGA GGC TCA GCA CAG AGA GAA TGA GTG ACC TCG AAC NM_018866.2 
MMP9 TGT ACA CAG GCA AGA CCG TG CTC CAG CAT CCA GTG CAT CG NM_013599.3 
MMP10 CCT TCA GAC TTA GAT GCT GCC GTA CTA CTA GTC GTG TCG TCG NM_019471.3 
IL1β GTA CAA GGA GAA CAA AGC AAC CTG TGC CTA AGG TAC CAC TTC NM_008361.4 
Ffar3 CTG GCT GTT GTG ACG CTT CGG TGA CAA ATT CAG AAC TCT NM_001033316.3 
Ffar2 CTT CTT GCA GCC ACA CTG CT CAC TCC TTG GAT GGC TCT TC NM_001168511.1 
Bacterial 16S rRNA gene Forward Reverse References 
Eubacteria ACT CCT ACG GGA GGC AGC AGT ATT ACC GCG GCT GCT GGC (145) 
Enterobacteriaceae GTG CCA GCA GCC GCG GTA A GCC TCA AGG GCA CAA CCT CCA 
AG 
(146) 
Bacteroides GGT TCT GAG AGG AGG TCC C GCT GCC TCC CGT AGG AGT (147) 
Mouse intestinal 
bacteroides 
CCA GCA GCC GCG GTA ATA GCG ATT CCG CAT ACT TCT C      (148) 
Clostridium coccoides ACT CCT ACG GGA GGC AGC GCT TCT TAG TCA GGT ACC GTC 
AT 
(149) 
Clostridium perfringens CGC ATA ACG TTG AAA GAT GG CCT TGG TAG GCC GTT ACC C (150) 
Segmented filamentous 
bacteria 
GAC GCT GAG GCA TGA GAG CAT GAC GGC ACG GAT TGT TAT TCA (151) 





CHAPTER 3. ROLE OF RETINOIC ACID ON THE REGULATION OF INNATE 
LYMPHOID CELL SUBSETS’ INTESTINAL MIGRATION 
3.1 Introduction 
 
Innate lymphoid cells (ILCs) do not have antigen receptors but play immune 
regulatory functions in a manner somewhat reminiscent of T cells (153). ILCs play 
important roles in host defense against pathogens and can mediate tissue inflammation 
(73, 105, 154). Three groups of ILCs with distinct characteristics in development and 
effector function have been identified. Group 1 ILCs (ILC1), including NK cells, are 
induced by the transcription factor T-bet and produce IFN-γ (155). The development of 
group 2 ILCs (ILC2), which produce IL-5 and IL-13, require ROR-α, Gata3, and Tcf7 
for development (156). Group 3 ILCs (ILC3) require RORγt and Gata3 for development 
and are composed of IL-17/IL-22-producing LTi cells, IL-17/IL-22/IFN-γ-producing 
ILCs, and IL-22-producing natural cytotoxicity triggering receptor (NCR)+ ILCs (91, 
157). The importance of these ILCs in mounting innate immunity and regulating 
inflammatory responses in the intestine and other mucosal tissues is now firmly 
established.  
         Migration of lymphocytes is regulated by chemokines and integrins (75, 158). 
Naïve T cells utilize CCR7 and CD62L to migrate to secondary lymphoid tissues. Upon 




regulate CCR7 and CD62L but up-regulate a chemokine receptor, CCR9, and an integrin, 
α4β7 (70, 71). CCR9+α4β7+ cells migrate to the small intestine, while CCR9-α4β7+ cells 
are likely to migrate into the colon. Acquisition of these receptors occurs in gut-
associated secondary lymphoid tissues such as mesenteric lymph node (MLN) and 
Peyer’s patches (PP). CCL25, a chemokine expressed in the small intestine (SI), activates 
CCR9 for adhesion triggering and chemotaxis (159). α4β7 binds MAdCAM-1, which is 
widely expressed on gut endothelial cells (160). It is generally accepted that innate 
immune cells such as NK cells, do not undergo a sophisticated trafficking receptor switch 
for specific migration into a tissue site. All ILC subsets are highly enriched in the 
intestine compared to other tissue sites. However, the mechanism for ILC enrichment and 
population in the intestine has been unclear.  
Recently, it has been reported that RA regulates the development, expansion, and 
effector function of ILCs. RA-RAR signaling is important for lymphoid tissue inducer 
cell (LTi cell) development in the gut tissue of the fetus (74). RA expands ILC3s but 
suppresses ILC2s in in the gut (73). In addition, RA promotes IL-22 expression by ILC3s 
through RARα (72). However, role of RA on ILC migration program have not been 
investigated, yet.  
We hypothesized that ILC migration to the intestine is not random but is regulated 
specifically by certain trafficking receptors. We investigated migration programs of ILC 
subsets and role of intestinal tissue factor, RA on the regulation of homing receptor 
expression in ILC subsets. We report here that retinoic acid induce homing receptor 
switches from lymphoid tissue receptor to gut homing receptor in ILC1 and ILC3 in the 




Hence, ILC subsets have conserved and diverse migration program for gut homing and 

























3.2 Materials & methods 
 
Animals 
All animal experiments in this study were approved by the Purdue Animal Care 
and Use Committee. All strains were kept at Purdue for at least 1 year. C57BL/6 mice 
were from Harlan. CD45.1 congenic (B6.SJL-Ptprca Pepcb/BoyJ), CD90.1 congenic 
(B6.PL-Thy1a/CyJ), Rag1-/- (B6.129s7-Rag1tm1Mom/J), Ccr7-/- (B6.129P2(C)-Ccr7tm1Rfor/J), 
and Itgβ7-/- (C57BL/6-Itgb7tm1Cgn/J) mice were purchased from the Jackson Laboratory. 
Ccr9-/- mice were obtained from described previously (161). VAD and VAN Rag1-/- or 
C57BL/6 mice were generated by feeding 0 and 2,500 IU/kg of retinyl acetate containing 
rodent diets (Harlan Teklad diets, Indianapolis, IN). Special diets were given to mice 
following birth and after weaning until they were 11-12 weeks of age. 
 
Identification of mature ILC subsets and bone marrow ILC progenitors 
Cells from intestinal lamina propria, PP, spleen, MLN, and blood were prepared 
as previously described. For ILC1s and ILC3s, cells were first stained with antibodies to 
following the common lineage markers: CD3ε (clone 145-2C11), CD5 (53-7.3), CD8α 
(53-6.7), CD19 (6D5), B220 (RA3-6B2), CD11b (M1/70), CD11c (N418), Ter119 (Ter-
119), F4/80 (BM8), Gr-1 (RB6-8C5), TCRβ (H57-597), TCRγδ (GL3), CD49b (DX5), 
and FcεR1α (MAR-1) and other antigens (CD45.2/104, CD90.2/53-2.1, CD90.1/OX-7, 
and/or CD127/A7R34), and then fixed and permeabilized for further staining for 
intracellular antigens (T-bet/eBio-4B10, GATA-3/TWAJ, RORγt/AFKJS-9 and/or 




markers mentioned above and NK1.1/PK136, CD90.2, CD90.1, CD127, Sca-1/D7, 
KLRG-1/2F1, T1/ST2 (DIH9), and GATA-3. Intraepithelial cells were stained with 
antibodies to the common lineage markers, NKp46 (29A1.4), and NK1.1. All antibodies 
were from BioLegend or eBioscience. Gating strategies for mature ILC subsets are 
described in Fig. 2.1. Isolated BM cells were stained with antibodies to CD127, Sca-1, 
CD25, KLRG-1 and BM lineage markers (CD3ε, CD5, CD8α, B220, CD11b, Gr-1, Ter-
119, TCRγδ, and NK1.1). BM ILC2P and relatively more mature KLRG-1+ ILC2 cells 
were respectively identified as Lin-CD127+Sca-1hiCD25+KLRG-1- and Lin-CD127+Sca-
1hiCD25+KLRG-1+ cells. The expression of homing receptors by ILCs and ILC2P was 
determined using antibodies to CCR7 (4B12), CCR9 (242503), α4β7 (DATK32), and 
CD103 (2E7). 
 
Cell isolation and culture 
Lineage negative cells (Lin-) were isolated from the spleen by depleting cells 
expressing CD3ε, CD5, CD19, B220, CD11b, CD11c, Ter119, F4/80, and Gr-1 
(splenocyte depletion markers) using biotin-labeled antibodies and anti-biotin beads 
(Miltenyi Biotec). ILC3s were isolated by FACS (Lin-NK1.1-KLRG-1-CD90hiCD127+) 
or MACS (Lin-NK1.1-KLRG-1-CD90hi). BM Lin- cells were prepared by depleting cells 
expressing the BM lineage markers and Ly-6B.2 (7/4) by MACS and used for the BM 
ILC2P in vivo short homing study. Lin- cells were cultured for 4 days in complete RPMI 
1640 medium (10% FBS) with ILC subset-specific condition. (ILC3: Cecal bacterial 
antigen (CBA, 10 µg/ml), IL-7 (20 ng/ml) and IL-23 (20 ng/ml); ILC1: CBA, IL-7 and 




(500 nM, a RARα antagonist), AM580 (10 nM, RARα agonist), AC55649 (10 nM, a 
RARβ2 agonist), or LE540 (500 nM, a pan-RAR antagonist), were added to culture. 
These chemicals were from Sigma-Aldrich or Enzo Life Sciences. For DC and ILC co-
culture, CD11c+ cells were isolated from spleen and MLN with CD11c microbeads 
(Miltenyi Biotec) (purity > 90%). 5 × 104  spleen and MLN-DCs, pulsed with CBA (10 
µg/ml) for 3 h, were co-cultured with 5 × 105 spleen Lin- cells in complete RPMI medium 
containing 10% FBS (non-heat inactivated) for 4 days. Cells were harvested and stained 
for HRs and ILC-associated antigens and transcription factors. 
 
Chemotaxis assay 
Spleen Lin- cells (5×105/well), cultured in the presence or absence of RA (10 nM) 
or Ro41-5253 (500 nM) in ILC subset-specific culture conditions for 4 days, were loaded 
in the upper chamber of Transwell inserts (Corning) and allowed to migrate to the lower 
chamber containing murine CCL25 (3 μg/ml, R&D Systems) for 3 h. The migrated cells 
in the lower chambers were harvested, stained with antibodies to identify ILC1s, ILC2s, 
and ILC3s, and counted by a time-based flow cytometry.  
 
In vivo migration studies  
For short-term migration of ILCs, cultured CD45.2+CD90.1+ WT and 
CD45.2+CD90.2+ HR-deficient spleen Lin- cells (10-15M cells) were co-injected i.v. into 
CD45.1 mice. Host mice were euthanized 20 hours later, and indicated organs were 
harvested. The numbers of injected ILC3s migrated into each organ or in the blood were 




calculated as below: Homing index of homing receptor-deficient ILC for organs A= 
[CD90.2+ HR-deficient- ILC in organ A] / [CD90.1+ WT ILC in organ A] ÷ [CD90.2+ 
HR-deficient ILC in injected cells] / [CD90.1+ WT ILC in injected cells]. Similar 
experiments were performed for control versus RA-treated ILCs. For migration of BM 
ILC2Ps, CD45.2+ Lin- BM cells, isolated from WT or HR-deficient BM (~35 M 
cells/mouse), were singly injected i.v. into CD45.1 mice. The host mice were sacrificed 
44 hours later, and indicated organs were harvested and examined for numbers of 
transferred ILC2 lineage cells in each organ. Migration efficiency of HR-deficient 
ILC2Ps to an organ was determined based on the normalized absolute numbers of 
transferred ILC2 lineage cells in each organ that were divided by the total numbers of the 
transferred ILC2 lineage cells in indicated organs. 
For long-term population of BM-derived ILC subsets, a 1:1 mixture of BM cells (5×106 
each) from WT mice (CD45.2+CD90.1+) and HR-deficient mice (CD45.2+CD90.2+) were 
co-injected i.v. into irradiated (2×500 cGy with a 3 hour interval) host mice (CD45.1) 
(The reconstitution efficiency: higher than 95% based on spleen). After 8 weeks, mice 
were sacrificed for examination of ILC subset frequencies and numbers. 
 
Confocal microscopy 
Ileum tissues were frozen in Tissue-Tek OCT Compound (Sakura), and 9-μm 
tissue sections were made using a cryostat (Leica). The sections were fixed in cold 
acetone, and stained with fluorochrome-conjugated antibodies to pan-cytokeratin (Clone 
AE1/AE3), CD90.2, and CD3 (Clone 17A2) or CD4. The images were collected with a 




Infection with C. rodentium and ILC3-enriched cell transfer 
VAN and VAD RAG1-/- mice were infected with C. rodentium (DBS100, 109 
CFU/mouse) and their weight changes (%), stool consistency, and bacterial burden were 
monitored. For ILC3 transfer into those mice, VAD mice were injected i.v. with WT 
control ILC3s, WT RA-treated ILC3s, or gut HR-deficient RA-treated ILC3s two times 
on day -2 and day 2 post-infection. Mice were sacrificed on day 9 post-infection.  
 
qPCR 
qPCR was performed as described before (162) to detect mRNA expression for 
Il22, Il17a and anti-microbial peptide genes in SI and proximal colon tissues. The 
primers information used for qPCR as followed.  
β-actin: Forward: AGAAGAGCTACGAGCTGCCTGAC Reverse: TACTCCTGCTT 
GCTGATCCACAT; IL17a: Forward: GAC TCT CCA CCG CAATG Reverse: CGG 
GTC TCT GTT TAG GCT; IL22: Forward: GGC CAG CCT TGC AGA TAA CAA 
Reverse: TCA GAG ACA TAA ACA GCA GGT CC; RegIIIβ: Forward: GAG GCC TGG 
AGG ACA CCT C Reverse: GTA TCC CGT TGA AGT GGA GTG T ; RegIIIγ: Forward: 











Student’s t-test (paired. Two-tailed) was used to determine significance of the differences 
between two groups. p values < or =  0.05 were considered significant. Repeated 
measures ANOVA was used to determine differences between two sets of weight change 
data (SAS, version 9.2, SAS Institute Inc. Cary, NC). All error bars indicate standard 























ILC subset distribution in various tissues 
ILC subsets are widely distributed in various tissues but most densely populate 
mucosal tissues, where their innate immune functions can be effectively utilized. For 
example, ILCs in the intestines and lungs play significant roles in the regulation of innate 
immunity against pathogenic microbes. ILCs are also detected in peripheral tissues and 
regulate host metabolism. ILC subsets differently populate various tissues, which may 
indicate their functional relevance to the immunological regulation of certain tissues. We 
examine ILC subset (NK cells, ILC1, ILC2, and ILC3) in different tissues sites. Figure 
3.1 shows the proportions of ILC subsets in each tissue site. NK cells (CD3-CD19-
CD127-NKp46+NK1.1+ or intestinal NK cells: CD3-CD19-CD127-RORγt-NKp46+NK1.1+ 
cells) are mostly present in secondary lymphoid tissues rather than intestinal tissue. 
Among the total population of ILCs, NK cells comprise ~95% in the spleen and MLN 
(Fig. 3.1). NK cells were also detected in lung and fat at modest levels. Non-NK ILC1s 
are broadly distributed in various tissues, but they are a minor population compared to 
NK cells and other ILC subsets. ILC2s (Lin-CD90+CD127+RORγt-GATA3+ cells) were 
detected in the most of the analyzed tissues. It is noteworthy that ILC2s make up the 
largest ILC population in the colonic lamina propria, skin, and fat tissue. In fat tissue and 
skin, ILC2s comprised ~45% and ~90% of total ILCs, respectively (Fig. 3.1). This may 
related to their regulatory functions such as allergic responses and fat metabolism. ILC3s 




summary, the distinct distribution of ILC subsets suggests specific roles of ILC subsets in 
different tissue sites.  
 
ILCs express homing receptors in tissue- and subset-specific manner 
First we attempted to detect ILCs in different tissues. We established gating 
strategy to detect total ILCs (Lin-CD90+CD127+) and ILC subsets (ILC1: Lin-
CD127+CD90+Eomes-RORγt-T-bet+, ILC2: Lin-NK1.1- CD127+CD90+Sca-1+KLRG-
1+GATA-3+), and ILC3: T-bet- or T-bet+ Lin-CD127+CD90+RORγt+GATA-3- (Fig. 3.2). 
With these gating strategies, we examined homing receptors (HR) expression by ILCs in 
various tissues to determine whether ILCs express HR in a tissue dependent manner. 
Interestingly, ILCs display distinct HR expression pattern between secondary lymphoid 
and intestinal tissues (Fig. 3.3). For example, CCR7 was highly expressed by in splenic 
and mesenteric lymph node (MLN)-ILCs, whereas CCR9 and α4β7 was highly expressed 
by the intestinal ILCs (Fig. 3.3). These data indicate that ILCs express HRs in a tissue-
specific manner. Next, we also examine HR expression in ILC subsets to determine 
whether HR expression by ILCs is in a subset-specific manner. CCR7 is highly expressed 
by splenic and MLN-ILC3s and MLN-ILC1s (Fig. 3.4). However, ILC2s did not express 
CCR7 in either secondary lymphoid or intestinal tissues (Fig. 3.4). Many CCR9+ or 
α4β7+ ILC1s and ILC3s were detected in the small intestine and colon. CCR9 expression 
was uniformly high on ILC2s from all organs, but α4β7 expression was reduced in 
intestinal ILC2s (Fig. 3.4). In general, ILC3s resemble ILC1s in terms of HR expression 
profiles but are different than ILC2s. These results suggest that ILC subsets have shared 




Tissue-specific HR expression required to populate ILCs in certain tissue sites 
Since ILCs express HRs in a tissue dependent manner, we investigated whether 
HR is functionally important for ILCs populating specific tissue sites. To do that, we 
examined ILCs in mice deficient in the tissue-specific HRs: CCR7, CCR9, and Itgβ7. 
Total ILCs were significantly decreased in the MLN of Ccr7-/- mice (Fig. 3.5). ILC 
numbers were decreased specifically in the SI of Ccr9-/- mice (Fig. 3.5). ILCs were 
decreased in both the small intestine (SI) and colon of Itgβ7-/- mice. In contrast, ILCs 
were increased in the spleen and MLN of Ccr9-/- or Itgβ7-/- mice (Fig. 3.5). We also 
confirmed that total ILC numbers in the SI were decreased in CCR9- or Itg-β7-deficient 
mice by confocal microscopy (Fig. 3.7). More specifically, we examined ILC subset 
frequencies and numbers in those HR-deficient mice. CCR9 deficiency affected ILC2 
numbers in the small intestine (Fig. 3.6). In contrast, ILC1s and ILC3s were decreased in 
the small intestine and colon of Ccr9-/- mice and Itgβ7-/- mice, respectively. ILC1s and 
ILC3s were decreased in the MLN of Ccr7-/- mice. CCR9 is highly expressed by 
intraepithelial (IEL)-ILC1 (Lin-NKp46+NK1.1+ cells) (Fig 3.8). In line with this, IEL-
ILC1 numbers were moderately decreased in the small intestine of CCR9-deficient mice 
(Fig 3.8). A few IEL-ILC1s expressed α4β7 and CD103 (Fig. 3.8).  
 
RA induces HR switch from secondary lymphoid tissue-HR to gut-HR in ILC1s and 
ILC3s 
We investigated the tissue-specific regulatory factors affecting gut-HR expression 




gut-HR in adaptive immune cells. Thus, we examined if RA induces the expression of 
gut-HR in ILCs. RA induced CCR9 and α4β7 expression on ILCs while reducing CCR7 
expression (Fig. 3.9A). Co-staining of CCR7 and gut homing receptors revealed that RA 
induces a switch from CCR7+CCR9-α4β7- to CCR7-CCR9+ and/or α4β7+ expression in 
total ILCs (Fig. 3.9B). It has been reported that RA affects the balance of ILC subsets. 
Therefore, there is the possibility that RA induced an altered balance of ILC subsets 
rather than expression of gut-HR. To rule out this possibility, we tested for a HR switch 
in each ILC subset. RA induced HR switches were observed in ILC1s and ILC3s but not 
in ILC2s (Fig. 3.10). 
Among RA receptors, the transcription factors RARα is the most highly 
expressed by ILCs (Fig. 3.11A). In line with this, AM580, an RARα agonist, efficiently 
induced gut HRs in ILC3s (Fig. 3.11B). LE540 (a pan-RAR antagonist) and Ro41-5253 
(an RARα antagonist) further decreased the basal expression levels of CCR9 and α4β7 
on cultured ILC3s (Fig. 3.11B). The chemotactic activity of ILC1s/ILC3s to CCL25 was 
increased by RA treatment, but was suppressed by Ro41-5253 (Fig. 3.12). ILC2s 
migrated to CCL25 as efficiently as RA-treated ILC1s and ILC3s. Dendritic cells (DCs) 
express retinal aldehyde dehydrogenases (RALDHs), which convert retinaldehyde to RA; 
therefore mucosal DCs are a major cellular source for RA in the intestine. When ILC3s 
were cocultured with MLN-DC in RA-free medium, MLN-DCs induced gut-HRs in 
ILC3s and ILC1s (Fig. 3.13A and B). Interestingly, MLN-DCs had higher capacity to 
induce HR switch in ILC1s and ILC3s compared to Spleen-DCs. RARα antagonist Ro41-




ILC3s. These results imply that mucosal DCs-derived RA induces a HR switch in 
intestinal tissue-associated lymphoid tissue such as the MLN. 
 
Vitamin A status affects HR expression by ILC1s and ILC3s, but not ILC2s 
From previous research, we found that RA is important for a HR switch in ILC1s 
and ILC3s in vitro. We further investigated the role of RA on HR expression by ILC 
subsets in vivo. We generated vitamin A normal (VAN) and vitamin A deficient (VAD) 
RAG1-/- mice to examine the HR phenotype of ILCs. As expected, VAD mice had 
reduced gut-HR expression in ILC1s and ILC3s of the small intestine (Fig. 3.14). 
However, CCR7 expression was only slightly increased compared to their counterparts in 
VAN mice (Fig. 3.14). However, vitamin A status did not affect the HR phenotype of 
ILC2s in vivo (Fig. 3.14). We also found that total ILC numbers were decreased in the 
intestines of VAD mice by flow cytometry and confocal microscopy (Fig. 3.15A and B). 
 
BM ILC2 progenitors express gut HRs and directly migrate to the intestine 
Since ILC2s broadly express gut-HR in secondary lymphoid and intestinal tissues. 
We assumed ILC2Ps acquire gut-HR expression in early stages unlike ILC1s and ILC3s. 
We could detect ILC2Ps in the BM by gating on Lin-CD45+Sca1highCD25+KLRG1+ or – 
cells (Fig. 3.16). Interestingly, those cells express the gut-HRs, CCR9 and α4β7, more 
highly compared to other Lin- cells (Fig. 3.17). Additionally, we tested whether 
expression of gut-HR by BM ILC2Ps is influence by vitamin A status. Gut HR 
expression by BM ILC2Ps was not affected in vitamin A deficiency (Fig. 3.17). Then, we 




transferred CD45.2 BM cells into CD45.1 congenic mice for a short-term migration assay. 
Surprisingly, up to 20-30% ILC2Ps were detected in intestinal tissues (Fig. 32.18). We 
also determined if gut-HRs affect ILC2Ps homing properties by a short term migration 
study. Results indicated that CCR9 is necessary for normal migration of ILC2Ps to the 
small intestine specifically, and Itg-β7 was required for migration of ILC2Ps to the MLN, 
small intestine, and colon. These results indicate that acquisition of gut HRs expression in 
the BM guides ILC2 migration to the intestine. 
 
Importance of RA-induced gut HR for ILC3 migration to the intestine 
We next asked if RA-induced CCR9 and α4β7 expression is important for 
migration of ILC3s to the intestine. We performed a short term migration study using 
CD45.2+ CD90.1+ RA-treated ILC3s and CD45.2+ CD90.2+ control ILC3s that were co-
injected into CD45.1+ CD90.2+ mice (Fig. 3.20). The RA-treated ILC3s were highly 
efficient in migrating to the small intestine and colon compared to control ILC3s (Fig. 
3.20). We also performed a short term migration study with HR-deficient ILC3s (Fig. 
3.20). We prepared RA-treated ILC3s (WT, Ccr9-/-, and Itgβ7-/-) or control ILC3s (WT 
and Ccr7-/- ILC3). Ccr9-/- was required for RA-treated ILC3 migration to the small 
intestine (Fig. 3.20). Results showed that Itgβ7-/- RA-treated ILC3s and Ccr7-/- ILC3s 
were not efficient in migrating to the intestine and MLN, respectively (Fig. 3.21). To see 
the long term effect of HRs of ILCs in migrating to lymphoid tissues and intestine, mixed 
BM chimeras were generated by mixed CD45.2 WT and HR-deficient BM cells 
transplanted into lethally-irradiated CD45.1 mice. Ccr7-/- ILC3s and Ccr9-/- ILC3s were 




ILC3s failed to normally populate the intestine (Fig. 3.22). Ccr9-/- ILC2s failed to 
populate the small intestine, and Itg-β7 deficiency slightly decreased the ILC2 population 
in the colon. These results indicate that the distinct expression of tissue-specific homing 
receptors expression determines the population of ILC subsets in the intestine and 
lymphoid tissues. 
 
RA-treated ILC3s complete with their HRs can effectively restore defective mucosal 
immunity in vitamin A deficient hosts 
VAD RAG1-/- mice are more susceptible to C. rodentium infection than VAN 
RAG1-/- mice and are deficient in ILC3s in the intestine (Fig. 3.23). These VAD mice had 
reduced IL-17 and IL-22 expression and antimicrobial peptide expression in intestinal 
tissues (Fig. 3.24A and B). We tested if RA-induced gut HRs are important for ILC3-
mediated anti-bacteria immunity against pathogenic bacteria. Only RA-treated ILC3 
transfer showed a protective effect in infected VAD RAG1-/- mice (Fig. 3.25). However, it 
is already reported that RA promotes ILC3 expansion and IL-22 expression, which could 
explain the protective function of ILC3s in VAD mice. To rule out this possibility, we 
performed the transfer of WT versus Ccr9-/- or Itgβ7-/- ILC3s into VAD mice (Fig. 3.26). 
These gut-HR-deficient ILC3s showed similar expansion and IL-22 expression induced 
by RA in cell preparation (not shown). Compared to Ccr9-/- and Itgβ7-/- ILC3s, WT 
ILC3s showed more effectiveness in protecting VAD mice (Fig. 3.26). In line with this, 
WT ILC3 transfer efficiently increased ILC3 numbers in intestines compared to Ccr9-/- 
and Itgβ7-/- ILC3s (Fig. 3.27). In addition, the transfer of RA-treated ILC3s restored the 
































Innate lymphoid cells (ILCs) are highly enriched in the intestine, and their 
importance in innate immunity has been well established. Recently, it has been reported 
that RA regulates innate lymphoid cell biology, including development, expansion, and 
effector function in the intestine. However, it is unclear how ILCs populate the intestine 
and if RA regulates their migration. Therefore, we focused our research on how ILCs 
migrate to the intestine and whether RA as a major intestine-specific cue controls ILC 
trafficking behavior. Our study has established the migration behavior of ILCs to the 
intestine. We identified that RA play a significant role in regulating ILC migration for 
population of and effector function in the intestine. 
We demonstrated that ILCs utilize gut-homing receptors, CCR9 and α4β7 to 
migrate into the intestine. α4β7 acts as an adhesion molecule to bind MadCAM-1, which 
is expressed broadly on intestinal endothelial cells (163, 164). α4β7 is required for 
migration to both SI and colon. The role of α4β7 for ILC migration into the whole 
intestine is well supported by our data that ILC1 and ILC3 in both SI and colon express 
α4β7. The CCR9-specific chemokine, CCL25, is specifically expressed in the small 
intestine (165). SI ILCs most highly express CCR9. Our data indicates that many of ILCs 
in the MLN also express CCR9, but CCR9-deficient mice have normal levels of ILCs in 
MLN. This result suggested the potential that the MLN may be a generating site for gut-
homing ILCs. MLN ILC3s were most affected in CCR7-/- mice, whereas intestinal ILC3s 




ILC3s were defective in migration only to SI, whereas Itg-β7-/- ILC3 were defective in 
migration to both colon and SI. CCR7-/- ILC3s were not efficient in migrating to the 
MLN. Thus, these results indicate that ILC3s utilize tissue-specific homing receptors to 
selectively migrate to different tissues.  
Interestingly, ILC1s and ILC3s can undergo sophisticated trafficking receptor 
switches to change their tissue tropism. Spleen ILCs do not express CCR9 or α4β7 at 
significant frequencies. However, dendritic cells isolated from MLN change the 
trafficking receptor expression phenotype of spleen ILC1s and ILC3s through production 
of RA. Thus, these ILCs have the potential to undergo trafficking receptor switches in a 
manner highly similar to gut-homing T and B cells. We demonstrated that RA is a key 
regulatory metabolite in up-regulating the expression of gut homing receptors on ILCs. 
Indeed, RA activates RARs, which function to induce the transcription of CCR9 and Itg-
α4 genes. We found that pan-RAR antagonist (LE540) or RARα antagonists (Ro41) can 
down-regulate the expression of gut-homing receptors on ILCs. This fact supports the 
idea that ILCs utilize RARα, for the induction of the gut-homing receptors. A question of 
interest is if all ILC subsets are regulated by RA. It has been documented that ILC2s are 
expanded in VAD mice whereas ILC3s are expanded by RA. These data indicate an 
apparent role of RA in regulation of ILC proliferation and survival in a subset-specific 
manner. Regarding homing receptor expression, ILC subsets differ in expression of 
CCR9 and α4β7. ILC1s and ILC3s highly expressed the two gut HRs only in the 
intestine, but the number of ILC2s expressing α4β7 were lower than ILC1s and ILC3s in 




ILC2s do not express CCR7 in both secondary lymphoid and intestinal tissue. In VAD 
mice, we also found correlating discrepancies in ILC subsets. Vitamin A deficiency 
affects HR expression patterns in ILC1s and ILC3s but not in ILC2s. These results 
suggest that ILC2s have different migration programs from ILC1s and ILC3s. In fact, 
BM ILC2Ps express CCR9 and α4β7 in bone marrow. And BM ILC2Ps can directly 
migrate to intestine, largely independent of gut-homing receptor expression. Unlike 
ILC1s and ILC3s, ILC2s do not undergo a HR switch in peripheral tissue, but rather they 
acquire gut HR expression during an early development stage. 
ILC3 deficiencies induce an impaired IL-22-antimicrobial peptide axis, leading to 
defective intestinal immunity (166). In this regard, the decreased immunity to C. 
rodentium infection in VAD mice is, in part, due to reduced numbers of ILC3s in the 
intestine. We demonstrated the possibility that the homing behavior of ILC3s can be 
changed by RA ex vivo to efficiently induce migration to the intestine and restore 
mucosal immunity in VAD mice. Importantly, without the expression of gut HRs, RA-
treated ILC3s were not able to provide effective immunity to mucosal pathogens, 
underlying the importance of the migration ability in determining the effector function of 
ILCs. 
The results provided novel insights into the migration program of ILCs to the 
intestine. ILC1s and ILC3s can reprogram their trafficking receptor expression to migrate 
into the intestine, a process regulated by RA. This indicates that certain innate immune 
cells possess sophisticated migration programs in a manner similar to adaptive immune 
cells. For ILC2s however, the expression of gut HRs occurs not in the periphery but early 




RA, regulates the gut migration program of certain ILC subsets, with implications for 

























3.5 Summary and future directions 
 
We reported that the vitamin A metabolite retinoic acid, produced by intestinal 
dendritic cells, is required for homing receptor switch from lymphoid tissue receptor, 
CCR7 to gut homing receptors, CCR9 and α4β7 by ILC1s and ILC3s. ILC3s deficient in 
expression of CCR9 and α4β7 were defective in not only their migration but also effector 
function in the intestine. In contrast, ILC2s acquire gut homing receptors in a largely RA-
independent manner during their development in the bone marrow and can migrate 
directly to the intestine. Thus, distinct programs regulate the migration of ILC subsets to 
the intestine for regulation of innate immunity. Beyond the gut homing of ILCs, ILC 
migration program to other tissue sites such as lung, skin, and fat need to be investigated 













Figure 3.1 Tissue distribution of ILC subsets. 
Average percent frequencies of NK, ILC1, ILC2, and ILC3 in total ILCs in indicated 
tissues are shown. NK cells were identified based on CD3-CD19-CD127-NKp46+NK1.1+ 
(most tissues), CD3-CD19-RORγt-NKp46+NK1.1+ (intestinal LP).  ILC1 were identified 
by Lin-RORγt-CD127+NKp46+NK1.1+. ILC2 were identified by Lin-
CD127+CD90+KLRG1+GATA3+ (most tissues), Lin-CD90+CD25+GATA3+ (spleen and 
skin), or Lin-CD127+CD90+T1/ST2+GATA3+ (lung and Fat) phenotype. ILC3 were 
identified by Lin-GATA3-CD127+CD90+RORγt+ phenotype. MLN, mesenteric lymph 







Figure 3.2 Gating strategies for ILC subsets in small intestine. 
Cells were isolated from the small intestine of C57BL/6 mice and stained with antibodies 
to lineage-specific antigens and indicated ILC-associated antigens. ILC1 (Lin-
CD127+CD90+Eomes-RORγt-T-bet+), ILC2 (Lin-NK1.1- CD127+CD90+Sca-1+KLRG-
1+GATA-3+), and ILC3 (T-bet- or T-bet+ Lin-CD127+CD90+RORγt+GATA-3-) subsets 








Figure 3.3 HR expression by total ILCs in various tissues. 
Expression of CCR7, CCR9 and α4β7 by total ILCs (Lin-CD90+CD127+) in secondary 
lymphoid tissues and the intestine. Cells were isolated from WT mice and flow cytometry 
was performed. Gating strategies were used as described in legend for figure 3.2. Isotype 
(IgG2a/b) antibodies were used for negative control staining. *Significant differences 









Figure 3.4 HR expression by ILC subsets in lymphoid and intestinal tissues.  
Expression of homing receptors by ILC subsets in the spleen, MLN, SI, and colon. Data 
from RAG1-/- or C57BL/6 mice were essentially identical and combined (n=15). Gating 
strategies for ILC subsets are shown in Fig. 2.1. *Significant differences (p<0.05) from 
ILC2.  **The spleen T-bet+ ILC3 population was very small (~0.1% of Lin-






Figure 3.5 Tissue-specific homing receptors are required for ILCs population in 
tissues. 
Frequencies of Lin-CD90+CD127+ total ILCs in lymphoid tissues and the intestine of WT, 
Ccr7-/-, Ccr9-/- or Itgβ7-/- mice. Dot plots show Lin- cells. Pooled data obtained from at 













Figure 3.6 Gut HRs required for normal numbers of ILCs in intestines. 
CD3-CD90+ ILCs in the small intestine of WT, CCR9-/- or Itgβ7-/- mice were imaged by 
laser scanning confocal microscopy. Frozen sections were stained by CD3, CD90, and 
pan-cytokeratin. Average numbers of CD3-CD90+ ILCs per villus and section are shown 









Figure 3.7 Tissue-specific HRs required for normal population of ILCs. 
Frequencies of ILC subsets (ILC1, ILC2, and ILC3) in lymphoid tissues and the intestine 
of WT, Ccr7-/-, Ccr9-/- or Itgβ7-/- mice. Relative values of ILC numbers in HR-deficient 
mice to those of WT are showing. Pooled data obtained from at least 3 different 










Figure 3.8 HR expression by intraepithelial ILC1s and their numbers in gut-HR-
deficient mice. 
(A) Expression of CCR9, α4β7, and CD103 by intraepithelial ILC1s (Lin-
NKp46+NK1.1+ cells) and γδ T cells in the small intestine. (B) Numbers of intraepithelial 
ILC1s in the small intestine and colon of WT, CCR9-/-, and Itg-β7-/- mice. *Significant 







Figure 3.9 Retinoic acid induced HR switch from 2nd LT-HR to gut-HR in ILCs. 
(A) Induction of gut homing receptors and down-regulation of CCR7 on ILCs by RA. (B) 
Induction of a homing receptor switch from CCR7 to CCR9 and α4β7 in cultured ILCs 
by RA. Expression of HRs on Lin-CD90+CD127+ ILCs was assessed after the culture of 
spleen Lin- cells for 4 days with RA or Ro41-5253 (an RARα antagonist).  For panel B, 








Figure 3.10 RA induces a HR switch from CCR7 to CCR9 and α4β7 in ILC3s and 
ILC1s but not ILC2s. 
HR expression in ILC1s, ILC2s, and ILC3s cultured with RA or Ro41. ILC subset- 
specific culture conditions were used. (ILC3: Cecal bacterial antigen (CBA, 10 µg/ml), 
IL-7 (20 ng/ml) and IL-23 (20 ng/ml); ILC1: CBA, IL-7 and IL-15 (20 ng/ml); ILC2: IL-
















Figure 3.11 RA receptor expression and impact of RAR agonists and antagonists on 
HR expression in ILC3s. 
(A) RA receptors expression was examined in total ILC and CD4+ T-cells by qPCR. ILCs 
(Lin-CD90+ cells) and CD4+ T-cells were isolated from WT-spleen. (B) Splenic ILCs 
were cultured in an ILC3 culture condition in the presence of indicated RAR agonists and 
antagonists. Cultured cells were stained for HR and ILC3 markers. Pooled data obtained 









Figure 3.12 Impact of RA and Ro41 on chemotaxis of ILC subsets. 
Splenic ILCs were cultured in specific ILC culture condition as described in the legend 
for fig. 3.10. Cultured cells were harvested and utilized for chemotaxis assay. Briefly, 
spleen Lin- cells (5×105/well), cultured in the presence or absence of RA (10 nM) or 
Ro41-5253 (500 nM) for 4 days, were placed in the upper chamber of Transwell inserts 
and allowed to migrate to the lower chamber containing murine CCL25 (3 μg/ml) for 3 h. 
The cells in the lower chambers were collected, stained with antibodies to identify ILC1, 
ILC2 and ILC3, and counted by a time-based flow cytometry. Pooled data obtained from 











Figure 3.13 Mucosal DCs-derived RA induces the expression of gut HRs  
in ILC3s and ILC1s. 
(A) Mucosal DCs induce a homing receptor switch in ILC3s. (B) Mucosal DCs induce 
the homing receptor switch in ILC1s. CD11c+ DCs, freshly isolated from spleen or MLN, 
and spleen Lin- cells were co-cultured (ratio=1:10, 4 days) for 4 days in the presence of 
Ro41-5253 or DEAB (an RALDH inhibitor). Pooled data obtained from at least 3 







Figure 3.14 Vitamin A deficiency reduces expression of gut HR by ILC3s and ILC1s. 
Expression of HRs by ILC subsets in the small intestine of VAN and VAD mice. Mice 
were fed with vitamin A deficient (VAD) or normal (VAN) diets for 11-12 weeks before 
examination of ILC subsets. SI-LP cells were isolated and stained by antibodies for HRs 
and ILC subset markers. Flow cytometry was performed. Pooled data obtained from at 











Figure 3.15 Decreased ILCs in the intestine of VAN and VAD RAG1-/- mice. 
(A) Confocal imaging of ILCs Average numbers of CD90+ ILCs per each villus and 
section are shown in the graph. IHC was performed to detect total ILCs in the intestine. 
(B) Total ILCs (Lin-CD127+CD90+ cells) numbers in VAN and VAD mice. Flow 
cytometry was performed. Mice were fed with vitamin A deficient (VAD) or normal 
(VAN) diets for 11-12 weeks before examination of ILC subsets. Pooled data obtained 
from at least 3 different experiments (n=12) are shown. *Significant differences (p<0.05) 








Figure 3.16 Gating strategies for BM ILC2 progenitors. 
BM cells were stained with antibodies to the “BM lineage markers” markers (CD3ε, CD5, 
CD8α, B220, CD11b, Gr-1, Ter-119, TCRγδ, and NK1.1), CD127, Sca-1, CD25, CD45.2, 
and KLRG-1. BM ILC2Ps were identified as Lin-CD127+CD45.2+Sca-1highCD25+KLRG-













Figure 3.17 Expression of gut HRs by BM ILC2Ps in VAN and VAD mice. 
Gut-HR expressions by BM ILC2P of VAN and VAD mice were examined by flow 
cytometry. Mice were fed with vitamin A deficient (VAD) or normal (VAN) diets for 11-
12 weeks before examination of ILC2P. KLRG1 staining was used to differentiate mature 
and immature ILC2 lineage cells in BM. Pooled data obtained from 3-7 different 













Figure 3.18 BM ILC2Ps can directly migrate to the intestine. 
(A) Tissue distribution of BM KLRG-1- and KLRG-1+ ILC2 lineage cells 44h after cell 
transfer (i.v.). Lin- Ly-6B.2- BM cells were injected i.v. into host mice and sacrificed 44 
hours later. (B) Representative dot plots for migrated BM-derived cells. The “Lin” 
mixture refers to the “BM lineage markers.” For migration of BM ILC2P, CD45.2+ Lin- 
BM cells, isolated from WT mice were singly injected i.v. into CD45.1 mice. The host 
mice were sacrificed 44h later, and indicated organs were harvested and examined by 
flow cytometry for numbers of transferred ILC2 lineage cells in each organ. Pooled data 








Figure 3.19 Gut HR expression is required for BM ILC2P migration to the intestine. 
Short term migration of WT versus gut HR-deficient BM ILC2P. Lin- Ly-6B.2- BM cells 
were injected i.v. into host mice and sacrificed 44 hours later. Migration efficiency of 
HR-deficient ILC2P to an organ was determined based on the normalized absolute 
numbers of transferred ILC2P in each organ that were divided by the total numbers of the 
transferred ILC2P in indicated organs.*Significant differences (p<0.05) from WT. Pooled 






Figure 3.20 Short-term homing of control versus RA-treated ILC3s to the gut and 
2nd LT. 
Spleen cells, depleted of cells expressing the “splenocyte depletion markers” mentioned 
in the Materials and Methods section, were cultured for 4 days in an ILC3 culture 
condition (commensal bacteria extract, IL-7, and IL-23) for 4 days. Cultured cells were 
utilized for short term (20 hr) migration study as described in material & method. Pooled 
data obtained from 2-3 different experiments (n=7-10) are shown. *Significant 







Figure 3.21 RA-induced gut HR expression is required for efficient short-term 
migration of ILC3s to the intestine. 
Short-term homing of WT versus homing receptor-deficient ILC3. Spleen cells, depleted 
of cells expressing the “splenocyte depletion markers” mentioned in the Materials and 
Methods section, were cultured for 4 days in an ILC3 culture condition (commensal 
bacteria extract, IL-7, and IL-23) for 4 days. The cells, except Ccr7-/- and matching WT 
cells, were treated with RA for the homing experiment. Short term migration studies were 
performed as described in material & method.*Significant differences (p<0.05) from 












Figure 3.22 Gut HRs required for long term population of ILCs. 
A long-term competitive population study of WT and homing receptor-deficient ILC 
subsets following mixed (1:1) BM transfer from CD45.2+CD90.1+ WT and 
CD45.2+CD90.2+ homing receptor-deficient mice.  The ILC subsets were examined in the 
indicated organs 8 weeks after the mixed BM transfer. Pooled data obtained from 2-3 
different experiments (n=7-10) are shown. *Significant differences (p<0.05) from control 












Figure 3.23 VAD RAG1-/- mice are more susceptible to C. rodentium infection. 
Mice were fed with vitamin A deficient (VAD) or normal (VAN) diets for 11-12 weeks 
before examination of anti-bacterial immunity. VAN and VAD RAG1-/- mice were 
infected with C. rondentium. Infected mice were monitored for weight change (%), stool 
consistency, and bacterial load in feces and peripheral tissues. Stool consistency scores 
were measured as follows: 0, normal stool; 1, soft stool; 2, mild diarrhea; 3, severe 





































Figure 3.24 VAD mice have an impaired ILC3 response in the intestine. 
Reduced cytokines and antimicrobial peptide expression (A), and intestinal ILC3 
numbers (B) in VAD mice with or without infection. Mice were fed with vitamin A 
deficient (VAD) or normal (VAN) diets for 11-12 weeks before examination of ILC3 
responses. Infected mice were euthanized at 6 days post infection. qPCR was performed 
for examination of expression of cytokines and antimicrobial peptides in intestinal tissues. 









Figure 3.25 Protective effects of control and RA-treated ILC3s in infected VAD 
mice. 
Purified ILCs (Lin-NK1.1-KLRG-1-CD90high) were cultured with RA (10 nM) in an ILC3 
culture condition (commensal bacteria extract, IL-7, and IL-23) for 4 days for the cell 
transfer. Control and RA-treated ILC3s were transferred into VAD mice and infected 
with C. rodentium. Weight change and C. rodentium load were monitored.  Pooled data 
obtained from 2 different experiments (n=7-8) are shown. *Significant differences from 











Figure 3.26 Gut homing receptors are required for optimal ILC3 effector function 
during C. rodentium infection. 
Protective effects of WT versus gut homing receptor-deficient RA-ILCs on C. rodentium 
infection. Purified ILCs from WT, Ccr9-/-, or Itgβ7-/- mice, were cultured with RA (10 
nM) in an ILC3 culture condition for 4 days before the cell transfer. Weight change (A), 
stool scores (B), and pathogen burden (C) were determined. Stool consistency scores 
were measured as follows: 0, normal stool; 1, soft stool; 2, diarrhea; 3, diarrhea and anal 
bleeding. Pooled data obtained from 2 different experiments (n=7-8) are shown. 







Figure 3.27 Tissue distributions of ILC3s following adoptive transfer of WT or gut-
HR-deficient ILC3s into VAD mice infected with C. rodentium. 
(A) ILC3 numbers in various tissues of infected VAD mice after ILC3 enriched cell 
transfer. (B) Representative dot plots for ILC3 in the colon. Lin-CD127+ cells are shown. 
VAD mice were injected i.v. with WT RA-ILC3 or HR-deficient RA-ILC3 two times on 
day -2 and 2 post-infection with C. rodentium. After infection, mice were monitored for 
anti-bacterial immunity. Mice were sacrificed on day 9 post-infection. Pooled data 
obtained from 2 different experiments (n=7-8) are shown. *Significant differences from 








Figure 3.28 Expression of ILC3 cytokines and antimicrobial peptides following 
adoptive transfer of WT or gut HR-deficient ILC3s into VAD mice infected with  
C. rodentium. 
VAD mice were injected i.v. with WT RA-ILC3 or HR-deficient RA-ILC3 two times on 
day -2 and 2 post-infection with C. rodentium. Mice were sacrificed on day 9 post-
infection. Colon tissues were harvested after infection. qPCR was performed. Pooled data 
obtained from 2 different experiments are shown. *Significant differences between VAN 








Figure 3.29 Distinctive trafficking receptor switches among ILC subsets. 
ILC3s express CCR7 in secondary lymphoid tissues but down-regulate CCR7 and up-
regulate gut HRs in response to RA produced by DCs to migrate to the intestine. ILC1s 
have similar migration patterns to ILC3s, but ILC2s do not undergo such a trafficking 
receptor switch. Rather, ILC2s express gut HRs in the bone marrow at the ILC2P stage 
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